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Abstract 
Previous studies identified a distinct region of interstital deletion at c8p12 
locus in colorectal cancer. Deletions at c8p12 were more frequent in early 
than advanced colorectal tumours. Further studies defined more closely this 
interstitial deletion, implicating a cluster of genes close to marker 085259 in 
early colorectal tumours. Although interstitial deletions normally correspond 
to tumour suppressor genes, the above findings suggest that this region 
contains genes with tumour suppressive and oncogenic effects. We 
investigated NRG1 , one of the genes in this region in colorectal 
tumourigenesis. 
To determine the expression profile of NRG1 , multiple approaches were 
utilised. Results from these studies identified deletion (loss of one allele) of 
NRG1 in early colorectal tumours. Increased expression of NRG1 protein 
was identified in advanced tumours compared to early colorectal tumours and 
adenomas. A significant correlation between NRG1 protein expression and 
erb82 protein overexpression was identified. Although the range of NRG1 
isoforms expressed was qualitatively similar throughout tumour progression, 
semi-quantitative real-time RT -PCR, showed overall decreased expression in 
early tumours compared with normal tissue. In advanced cancers, the results 
were more heterogeneous, but no consistent pattern emerged between the 
cases investigated. 
Although these studies did not demonstrate any functional relationship, the 
data strengthens the candidacy of a role for NRG1 in colorectal tumour 
progression. 
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Chapter 1 
Introduction 
1 
1.1 Colorectal cancer 
Colorectal cancer is the second most common cause of cancer -related deaths in 
the western world with an incidence of over 30 000 cases being diagnosed per 
annum in the U.K (Conlin et al. , 2005; Leslie et al. , 2002; Jepson et al., 2005). 
Despite improvements in medical and surgical treatments the overall 5-year 
survival is around 40% (Houlston, 2001 ; Leslie et al., 2002; Association of 
Coloproctology of Great Britain and Ireland, 2001 ). The high incidence of 
colorectal cancer with a modest improvement in overall survival highlights the 
need for early detection, prevention and improvements in treatment (The 
Association of Coloproctology of Great Britain and Ireland, 2001 ). 
1.1. 2 The adenoma- carcinoma sequence 
The fundamental concept of colorectal cancer involves the stepwise progression 
of normal colonic mucosa to dysplasia and ultimately to carcinoma through the 
accumulation of multiple genetic events including chromosomal abnormalities, 
genetic mutations and epigenetic changes thought to be critical in the 
development of colorectal cancer (Fearon and Vogelstein, 1990; Hamilton 1992; 
Massa et al., 1999; Reid et al. , 1999; Leslie et al., 2002; Soreide et al. , 2006; 
Leslie et al. , 2003; llyas et al. , 1999; Chung et al., 2000; Conlin, 2005). 
Fearon and Vogelstein (1990) proposed that a series of genetic events occurred 
at key stages in the adenoma-carcinoma sequence, which involved mutational 
activation (gain of function mutations) of oncogenes such as ras, and inactivation 
(loss of function mutations e.g. loss of both alleles) of tumour suppressor genes, 
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such as APC and TP53 in the developmenUprogression of colorectal cancer. 
These functional gain and loss of genes in cancer cells is mirrored by the 
acquisition of chromosomal aberrations (Reid et al. , 1999). 
1.1.3 Chromosomal aberrations 
Chromosomal aberrations involving the loss or gain of specific regions of the 
genome have been reported extensively in solid tumours (Albertson et al. , 2003; 
Qin, 2002). Alterations (gains or losses) in DNA copy number, increase with 
cellular atypia, and seem to correlate with disease progression (Reid et al., 1999). 
In colon cancer, chromosomal aberrations have been detected in high grade 
dysplasia and adenomas, but are found increasingly in carcinomas Reid et al., 
1996). Similar findings have also been reported in tumours of the breast, brain 
and cervix uteri where an increase in the prevalence of chromosomal copy 
number has been reported with progression towards advanced stage disease 
(Schrock et al., 1994; Schrock et al. , 1996; Reid et al., 1995; Reid et al. , 1996; 
Heselmeyer et al. , 1996; Reid et al., 1999). 
Recurrent chromosomal aberrations are implicated in tumour development and 
often involve oncogenes and tumour suppressor genes, the expression levels of 
which are altered by these changes in the genome (llyas et al.,1999; Albertson et 
al., 2003; Qin et al., 2002; Reid et al. , 1999). Although a range of chromosome 
aberrations have been reported in colorectal cancer for the purpose of this study I 
will focus on chromosome 8. 
3 
1.1.4 Chromosome 8 and colorectal cancer 
Alterations in the short arm of chromosome 8 have been reported in a wide range 
of solid tumours including colon cancer (Bardi et al. , 2004; Wright et al., 1998). 
Deletions are the most common aberration in this region, identified through Joss of 
heterozygosity (LOH) studies (Qin, 2002; Chughtai et al., 1999). Although 
chromosome arm 8p allelic imbalance is frequently observed in colorectal cancer, 
the segment lost is generally poorly defined and interstitial deletions as well as 
loss of the whole 8p arm have been observed. Both oncogenes and tumour 
suppressor genes are thought to reside at these sites of recurrent alterations. 
LOH analysis has been used to define the precise loci targeted in chromosome 
arm 8p loss (Nakoa.et al., 2004; Halling et al., 1999). 
1.1.5 Loss of heterozygosity analysis of chromosome arm 8p in colorectal 
cancer 
Previous LOH analysis by our group identified two distinct centromeric regions of 
interstitial deletion, 8p11 .2-12 and 8p12 region, in colorectal cancer. Analysis of 
tumour phenotype revealed isolated 8p12 deletions to be associated with early 
colorectal disease (4/7 T1 , 3/11 adenomas vs 1/63 T2-T4; 2p=0.0001), while 
retention of this region was seen in advanced colorectal cancer (Chughtai et al. , 
1999). Fine mapping of the c8p 12 deletion region using a panel of P 1 artificial 
chromosome clones (PACs) established the deletion region lay between markers 
08887 (centromeric) and WRN gene (telomeric) as shown in Figure 1.1. 
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Figure 1.1: 8p12 DELETION REGION: The 8p12 deletion region was established to lie 
between marker 08887 centromerically and the WRN gene telomerically. Marker 
088535 and E8.1 C were found to be deleted and the WRN gene was found to be 
retained. The NRG 1 gene lies between marker E8.1 C and WRN gene. 
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Markers 088535, 088259 and E8.1 C were found to be deleted and WRN gene 
was retained in the colorectal tumour samples examined. The proportion of 
colorectal tumours showing deletion positively correlated with advancing tumour 
stage. This was true when considering deletion at marker 08887 (2/27 
adenomas, 2/9 T1 vs 6/12 T3-T4NO, 6/11 T3-T4N1 ; chi square for trend= 12.245, 
p=0.0005). However when considering deletion of the telomeric marker 088259, 
this trend was lost (2/27 adenomas, 7/1 0 T1 vs 6/12 T3-T 4NO, 2/11 T3-T 4N 1; chi 
square for trend =5.723, p=0.0167) (Adams, 2004). Deletion of maker 088259 
was more frequent in early colorectal cancer compared with advanced colorectal 
tumours as shown in Table 1.1 below. 
Stage Polyps T1-T2 T3-T4 
NOMO N1+ NOMO N1+ 
D8S87 12!27 (7%) 2/9 (22%) 0/0 6/12_{_50%1 ~11 _(_54o/~ 
085259 3/27 (11%1 7/10 _(IO~ 0/0 6/12 (50%) 2/11 (18%) 
Table 1.1: c8p12 deletions in colorectal tumours 
Reference to the Ensemble genomic database (http://www.ensembl.org) 
(Build35) identified six genes within the deletion region; a 1,3 fucosyl transferase, 
a dual specificity phosphatase 26, an RNA binding protein, a RING finger protein, 
lmportin-beta and Neuregulin-1 (NRG1) . 
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1.1.6 Candidate gene 
The a 1,3 fucosyl transferase gene is responsible for catalysing the transfer of 
glycosyl groups from donor to acceptor molecules (NCBI,UniProtKB/TrEMBL). 
The dual specificity phosphatase 26 (DUSP2.6) is involved in protein 
tyrosine/serine/threonine phophatase activity, the RNA binding protein is 
implicated in splicing, the RING finger protein is involved in mediating 
protein/protein interactions and protein ubiquinitation and lmportin-beta functions 
as a nudear transport protein (NCB I, UniProtKB/TrEMBL). Neuregulin-1 (NRG1), 
encodes a group of growth factors that belong to the epidermal growth factor 
(EGF) family of proteins. The protein products of NRG1 exert a variety of 
biological effects including cell proliferation, angiogensis, oncogenesis, cellular 
differentiation and apoptosis (Le et al. , 2002). Cleavage studies of neuregulin-1 
transmembrane proteins have reported oncogenic activity within the N-terminus of 
the protein (Montero et al., 2000) and the cytoplasmic tail is reported to have a 
pro-apoptotic effect (Weinstein et al. , 1998). 
Although hypotheses can be constructed for any one of the genes, in view of the 
dual properties of NRG1 proteins, this gene was a dear candidate for further 
study in colorectal cancer. 
7 
NRG1 isoforrns and facilitate their relative expression during development and 
adult life (Steinthorsdottir et al. , 2004). 
The neuregulin-1 proteins play a fundamental role in normal physiological 
development of the cardiac and nervous system. Pan-NRG1 knock out mice have 
been shown to have severe cardiac and nervous system developmental problems 
resulting in death during embryogenesis (Meyer et al., 1997) 
1.2.1 Structure of NRG1 isoforms 
Alternative splicing of the NRG1 gene results in isoforrns that differ in their N-
terminal sequence, the presence or absence of the transmembrane domain, and 
the type of EGF like domain i.e. a or~ and the C-terminus. The NRG1 isoforrns 
are classified in to type I isoforms which contain an lg-like domain at their N-
terrninus, type II isoforms which contain a signal peptide and kringle-like 
sequence at their N-terminus plus lg domain and finally type Ill isoforms have a 
hydrophobic domain with cysteine-rich sequence at their N-terminus and share 
only the common EGF domain with other isoforms. (Falls, 2003; Meyer et al. , 
1997; Lemke, 1996; Wen et al. , 1994; Wang et al., 2001). . 
A hydrophobic stretch of amino-acids at the c-terrninus of the EGF domain serve 
as the transmembrane domain and are utilised in membrane insertion (Wang et al 
2001 ; Falls, 2003; Lemke, 1996; Meyer et al., 1997). The type Ill NRG1 have a 
hydrophobic region within the cysteine-rich domain (CRD) which serves as a 
second transmembrane domain in theN-terminal fragment (Falls, 2003; Wang et 
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al. , 2001). A linker region also known as the "stalkn lies in between the bioactive 
EGF domain and transmembrane domain as shown in Figure 1.2. (Falls, 2003; 
Lemke, 1996; Montero et al., 2000). 
A Type-specific Cytoplasmic tail (CT c> sequences lg-likc Sca::cr EGF-Iike 
I I I I 
Type 1 I s1 s2 ° TMc a 
NDF/HRG/ARIA \ .1....1.. EGF c A~ l. ~* 
lga Jgh ~ •'- / ,....... ...._ ' c1c2 c3 / 
Ty~~ - ~ - -.,., li- ~ * C 
-"' ' li / -'/ 
Type Ill 
CRD--NRG 
SMOF 
CRD ...... -"' J.?- ,. / '----/ \ b 
,.. ~ - cmlllr.rm ;:'IFll 
- ' J to at! ';s* 
. f T,\fc.;VRG~· 
Figure 1.2: Structure of NRG1 isoforms 
CRD= cysteine - rich domain; EGF= epidennal growth factor like domain; Ig= immunoglobulin-like 
domain; Cfc= cytoplasmic domain C-terminal of the EGF domain; 51 52= spacer domains; TMc= 
transmembrane domain C-terminal of the EGF domain; Cfn and TMn = cytoplasmic and transmembrane 
domain N-tenninal of the EGF domain; * = stop codon. Hydrophobic regions that serve as transmembrane 
domains are indicated by black boxes. The hydrophobic sequence in the Type 11 N-terminal indicated by a 
hatched box is thought to function as a internal signal sequence rather than a transmembrane domain. 
Falls, 2003 
This structural diversity results in isoforms that are synthesised as soluble or 
transmembrane proteins and differentiates isoforms with respect to their in vivo 
functions. The bioactive EGF domain common to all NRG1 isoforms is essential 
for signalling activities (Marchionni et al. , 1993; Falls, 2003; Wen et al. , 1994; 
Lemke, 1996; Meyer et al. , 1997; Wolpowitz et al., 2000; Montero et al. , 2000). 
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1.2.2 Processing of NRG1 proteins 
The mechanism and cellular processing of transmembrane neuregulins has been 
the subject of several investigations. Numerous membrane anchored proteins 
such as amyloid precursor protein (APP), TGF-a, including NRG1 proteins (such 
as NDF, ARIA, HRG1) are subjected to proteolytic processing to release their 
extracellular domains (Burgess et al., 1995; Lu et al. , 1995; Han et al., 1999; 
Montero et al., 2000; Wang et al., 2001 ) 
The processing of NRG1 proteins has been studied in cultures of fibroblastic cells 
in which NRG1 isoforms have been expressed by transfection. These studies 
have indicated that the membrane bound NRG1 isoforms (such as NDF, HRG) 
are orientated with the amino-terminal ends exposed to the extracellular space 
with the carboxy terminal in the cytoplasm (Wang et al., 2001 ; Falls, 2003). The 
bioactive EGF domain is located extracellularly between the N-terminus and the 
transmembrane domain as shown in Figure 1.3. 
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Figure 1.3: Structure of type I neuregulin isoform. The bioactive EGF domain 
is located at the N- terminus. Cleavage of ectodomain occurs at the stalk region. 
(Falls, 2003) 
The transmembrane NRG1 proteins are proteolytically cleaved at the extracellular 
linker region which is considered a critical region for the regulation of balance 
between soluble and transmembrane forms of membrane anchored polypeptide 
factors (Montero et al. , 2000; Falls, 2003). Type I transmembrane neuregulins are 
cleaved in the stalk region like the type II NRGs resulting in the release of soluble 
bioactive EGF domain. 
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Cell ~ell interactions of NRG1 proteins 
Paracrine signalling by lg- (type I & II) neuregulins 
Paracrine signaling refers to short distance cell-cell communication mediated by 
diffusible signaling molecules. An example of this cell ~II interaction is seen 
during cardiac morphogenesis. The lg (type 1&11) neuregulin ligands are 
expressed in the endocardium, which is directly apposed to the developing 
myocardium where the receptors (erb82) for these ligands are expressed. The 
cleaved ligands interact with the erbB2 receptors via paracrine signalling (Falls, 
2003; Lemke, 1996). 
Autocrine Signalling 
NRG1 proteins have also been reported to be involved in autocrine signalling (Kim 
et al. , 1999) 
Juxtracrine signalling 
Studies on processing of N-terminal fragment of type Ill- f31 a and type l-f31 a 
neuregulin-1 isoforms revealed that type Ill neuregulin -1 proteins serve as 
juxtracrine signals {Wang et al., 2001 ; Falls, 2003). The type lll-f31 a and type l-
f31a neuregulins are identical in their EGF like domain, stalk, transmembrane 
domain but differ in their N-terminal. Wang et al. (2001) compared the processing 
of type I and type Ill f31a neuregulin-1 proteins in cell cultures. Western analysis of 
celllysates, cell surface biotinylation and immunocytochemical analysis revealed 
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that the amount of type Ill- ~1 a released in to the conditioned medium was less 
than type 1-~1a neuregulin-1 proteins. The type Ill- ~1a was found exposed at the 
cell surface as a transmembrane N-terminal fragment. Although the sequence of 
type 1-~1 a neuregulin-1 proteins is identical except for the N-terminus of the 
protein, processing of type Ill- ~1 a differed from type H31 a. This transmembrane 
N-terminal fragment is shown to act as a ligand at the cell surface. Evidence that 
type Ill- NRG serve as juxtracrine signals is seen in schwann cells in vivo 
(Morrissey et al., 1995; Salzer et al. , 1980). The schwann cells in direct contact with 
sensory neuron axons have a higher proliferative rate than schwann cells not in 
contact with axons. This proliferative effect was blocked by antibodies inhibiting 
neuregulin signalling, providing further evidence of type Ill -~1 a neuregulins 
interacting in a juxtracrine mode. (Falls, 2003; Morrissey et al., 1995; Salzer et 
al.,1980). These results suggest that Type 111-131 a is involved in cell-cell 
communication via juxtracrine signalling, whereas Type 1-~1 a interaction is 
through a paracrine mode (Falls, 2003; Wang et al., 2001 ). This is illustrated in 
Figure 1.4 below. 
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Figure 1.4: Membrane orientation and processing of neuregulin 1-131a and 
111-131a isoforrns. Proteolytic prosessing of type 1- ~1 a isoforms results in the 
release of a N-terminal fragment containing the bioactive EGF domain. 
Processing of type Ill- ~1a led to the release of N-terminal fragment containing the 
bioactive EGF domain, however most of the processing produced an N-terminal 
fragment that accumulated at the cell surface. 
(Falls, 2003) 
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1.2.3 Linker region of NRG1 proteins 
Deletion analysis of the linker region (connects the EGF domain to the 
transmembrane domain) has shown that it plays an important role in cleavage and 
release of the bioactive EGF domain of NRG1 isoforms (Montero et al. , 2000). 
Deletion in the linker region of the membrane bound pro-NRGa 2c altered the 
biological properties, resulting in intracellular entrapment of pro- NRG a 2c and 
decreased cell surface exposure of the mutant linker and entrapment at the cis-
Golgi. This identified that the linker region is implicated in surface sorting of 
transmembrane neuregulins (Montero et al., 2007). 
Cleavage of the extracellular domain has been reported to be regulated by the 
intracellular domain of membrane bound NRG1 isoforms. Shortening of the 
cytoplasmic tail or deletion of specific segments with in the cytoplasmic tail can 
lead the edodomain not being released (Liu et al., 1998). 
The processing of NRG1 proproteins has been shown to be stimulated by 
activation of protein kinase C, exposure of cells to phorbal esters, serum factors 
and is sensitive to inhibitors of metalloproteinases (Sunnarborg et al., 2002; 
Montero et al., 2000; Shirakabe et at, 2001). 
1.2.4 Enzymes responsible for cleavage of NRG1 proteins 
ADAMs (a disintegrin and metalloproteases) are a family of membrane anchored 
glycoproteins (Shirakabe et al. , 2001 ; Sunnarborg et al., 2002; Montero et al., 
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2000). Initial experiments using inhibitors of different protease families pointed to 
metalloproteinases as the enzymes responsible for cleavage of membrane protein 
ectodomains (Gearing et al., 1994; McGeehan et al. , 1994). Use of inhibitors 
allowed the identification of TNFa converting enzyme (TACE) as the enzyme that 
participates in the solubilisation of the TN Fa from its precursor (Moss et al., 1997). 
TACE is a type I membrane protein and contains several domains in the 
extracellular region, including disintegrin and metalloprotease domains 
characteristic of the ADAM subfamily of metalloproteases. TACE also participates 
in the cleavage of other transmembrane proteins (Horiuchi et al. , 2005). TACE 
also plays a role in the processing of NRG1 isoforms (Montero et al. , 2000). 
Montero et al. (2000) showed that cleavage of pro-NRG a2c was defective in 
fibrobalsts derived form TACE-/-animals that express an inactive form of the 
metalloprotease T ACE. 
1.3 Epidennal growth factor (EGF) receptors 
The neuregulin-1 proteins act as ligands for the epidermal growth factor (EGF) 
receptors also known as the Her I ErbB receptors (Falls, 2003; Lemke, 1996, 
Montero et al., 2008, Holmes et al., 1992; Meyer et al. , 1997; Wen., 1992; Beerfi., 
1995). The erb 8 receptors belong to the receptor tyrosine kinase family of 
proteins and currently four erbB receptors are known: erb81 , erb82, erb83 and 
erb84 (Beerli et al., 1995; Slikowski et al., 1994; Chen et al. , 1996). All family 
members have in common an extracellular ligand binding domain, a single 
membrane spanning region and a cytoplasmic protein tyrosine kinase domain 
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(Varden et al. , 2001 ; Riese et al., 1998; Olayioye et al. , 2000; Schlessinger et al. , 
2000). The neuregulin-1 ligands bind the extracellular domain of the erbB 
receptors leading to the formation of erb82:erb83 or erb82:erb84 heterodimers 
and trans-phosphorylation of erbB2/ erbB3 and erb82/ erbB4 (Falls, 2003; Meyer 
et al., 1997; Li et al. , 2007; Burgess et al. , 2003; Montero et al., 2008). The NRG1 
proteins are the preferred ligands for erb83/erbB4 receptors. The phosphorylated 
tyrosine residues of these receptors serve as docking sites for signalling 
molecules involved in the regulation of intracellular signalling cascade and serve 
as mediators of signal transduction (Oiayioye et al., 2000; Chen et al. , 1996; 
Pinkas-Kramarski et al., 1996). No soluble growth factor has been identified that 
binds to erbB2, but it is the preferred dimerisation partner of other erbB family 
members (Peles et al. , 1993). Erb83 is a binding receptor for NRG1 ligands but 
lacks intrinsic kinase activity and is not capable of signalling on its own (Funes et 
al., 2006). 
Interaction between receptor and ligand are crucial for cell-cell interaction 
(signalling) (Yarden et al., 2001 ; Riese et al., 1998; Olayioye et al. , 2000; 
Schlessinger et al. , 2000; Simon et al. , 2000; Walker et al. , 1998). Recent studies 
in primary cultures of human airway epithelial cells have demonstrated that 
activation of the erbB receptors is regulated by segregation of the receptor -ligand 
complex (Vemeer et al., 2003). In human airway epithelial cells the erbB 
receptors are located in the basolateral membrane. Heregulin, the ligand (a NRG1 
protein) for these receptors is present on the apical surface. Apicobasal cell 
polarity and tight junctions help to maintain segregation of the receptor from its 
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ligand. Disruption of tight junctions or of epithelial cell polarity because of injury, 
will lead to receptor-l igand interaction and cellular proliferation at the site of injury. 
Conversely, conditions in which epithelial polarity and tight junctions are disrupted 
can lead to a mitogenic receptor-ligand pair resulting in uncontrolled cell 
proliferation (Vermeer et al., 2003). 
Cleavage by y-secretase has been reported to result in the release of the soluble 
erbB4 fragment intracellular domain and facilitation of translocation of this 
fragment to the nudeus. The soluble erbB4 fragment contains a tyrosine kinase 
domain and it is possible that nuclear substrates may become phosphorylated by 
this soluble ErbB4 fragment, further extending the receptors mechanism of action 
(Ni et at., 2001 ). 
1.3.1 Regulation of ErbB receptor signalling 
Following initial activation events, ligand- induced internalisation and degradation 
of receptor-ligand complexes serves as an important mechanism for attenuating 
receptor mediated signalling alongside non degradative processes such as 
dephosphorylation by phosphatases (Wells et al. , 1990; Sorkin et al., 1993). 
Degradation of the erbB receptors is an important mechanism for signal 
attenuation (Warren et al. , 2006). Whereas the EGF domain of NRG1 isoforms is 
required for the formation of active receptor heterodimers, the N-terminal lg like 
domain is shown to be important in accelerating the removal of the activated 
erbB2 and erb83, primarily through enhanced degradation of Erb83 receptor and 
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in the case of erbB2, dephosphorylation with out receptor degradation appears to 
be more pronounced. Studies carried out by Warren et al. (2006) have shown 
that the physical presence of the N-terminal lg domain was required for these 
effects. The replacement of the lg domain with another protein of similar size still 
resulted in receptor degradation thus highlighting that the effect of the N-terminal 
lg domain was sequence -independent. 
Some of the negative regulators are actually secreted forms of the cell surface 
receptors themselves. The secreted receptor isoforms arise through regulated 
alternate mRNA processing and I or splicing events (Maihle et al., 2002). Lee et 
al. (2001) identified a secreted receptor isoform arising from the c-erbB3 gene. 
This study demonstrated that the secreted receptor isoform erbB3 is a naturally 
occurring inhibitor of heregulin. It blocks heregulin binding to cell surface 
receptors with high affinity, thereby inhibiting heregulin -induced stimulation of 
erbB2, 3 and 4 which has shown to be sufficient to effectively block heregulin 
stimulated cell growth. This novel erbB3 receptor isoform therefore has the 
potential to be a potent modulator of heregulin regulated cell proliferation and 
differentiation in normal human tissues. 
1.3.2 Overexpression of erb82 receptor and malignancy 
The erbB receptors are expressed in a variety of tissues of epithelial, 
mesenchymal, and neuronal origin where they play fundamental roles in 
development, proliferation and differentiation (Varden et al., 2001 ; Riese et al. , 
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1998; Olayioye et al., 2000; Schlessinger et al. , 2000; Simon et al. , 2000; Walker 
et al. , 1998). Moreover deregulated expression of erbB receptors in particular 
erb81 (Rusch et al., 1997; Bartlett et al., 1996; Messa et al. , 1998; Grandis et al. , 
1996) and erb82 has been implicated in the development and malignancy of 
numerous types of human cancers ( Colomer et al. , 2001 ; Ross et al., 1998). 
Overexpression of erbB2 has been observed in a significant proportion of breast 
and ovarian cancers, where it is associated with a poor prognosis (Siamon et al. , 
1989; Ross et al., 1998; Olayioye et al. , 2000; Kraus et al., 1987). 
Ampl ification of erb82 also known as the Her-2 gene is the major mechanism of 
overexpression of erb82 protein. In breast cancer, erb82 amplification is found to 
predict decreased survival more consistently than erb82 protein over expression 
(Kaptain et al. , 2001 ; Slamon et al. , 1987). 
Lee.J. C et al. (2002) investigated the expression of erbB proteins in colorectal 
tumours. Overexpression of erb83 was identified in early colon cancer, and the 
percentage coexpression of erb83 and erbb2 was significantly higher in early 
stage tumours. The prevalence of erb83 was reduced in late stage cancers. It 
was thought that heterodimerisation between erbb2 and erb84 may play a role in 
late stages of carcinogenesis. 
Studies of erb82 overexpression in colorectal cancer are inconsistent, with the 
reported prevalence of erbB-2 overexpression in colon cancer ranging from 0 -
83% (Ross et al. , 2001 ; Caruso et al. , 1996). In studies containing smaller 
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cohorts the rate of gene amplification was in the range of 0-30% (Tat et at., 1998; 
D'Emilia et at., 1989; Osako et al. , 1998). Variations in gene amplification data 
and erb82 protein overexpression are thought to be due to studies being 
underpowered and technical variables in the performance of 
immunohistochemistry (Nathanson et at., 2003). 
1.3.3 Clinical implication of erbB2 receptor overexpression 
Monoclonal antibodies to erb82 receptor (trastuzumab/herceptin) have been 
approved by the FDA (Federal Drug Administration) for treatment of tumours that 
express high levels of erb82 and are in use in patients with breast cancer (Xu et 
al., 2005). Recent studies have isolated a natural inhibitor of EGFRs called EGFR 
related protein (ERRP) which is present in most normal human epithelial cells (Yu 
et al., 2001 ). Recombinant ERRP has been shown to inhibit the growth of colon 
cancer cell lines (Yu et at. , 2001 ; Marciniak et at., 2003). In a study by Xu et at. 
(2005), recombinant ERRP was found to induce apoptosis in colon cancer cell 
lines in a dose dependant manner. In this study, Herceptin was found to 
attenuate heregulin (a NRG1 protein) induced activation of cancer cells 
expressing high levels of erbB-2 but did not induce apoptosis. Xu et al., (2005) 
concluded that as solid tumours express different EGFRs, identification of ERRP a 
pan-erbB inhibitor may provide therapeutic benefit to a broader patient population. 
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1.4 Neuregulin-1 Signalling 
Together with fundamental developmental roles (Garratt et at., 2006; Esper et at., 
2006; Falls, 2003), the NRG1 proteins have been shown to be involved in a 
number of cancer types including breast (Tsai et al. ,2003; Guerra-VIadusic et al. , 
1999), ovarian (Gilmour et at., 2002), endometrial (Srinivasan et at., 1999), colon 
(Venkateswarlu et at. , 2002), lung (Gollamudi et at. , 2004; AI Moustafa et al. , 
1999), thyroid (Fiuge., 2000), glioma (Flores et at., 2000; van der Horst et at. , 
2005), medulloblastoma (Gilbertson et at., 1998) and head and neck cancers 
(O'charoenrat et at. , 2000; Breuleux, 2007). 
A range of pathways have been reported to be activated by neuregulin-1 proteins 
including the phosphatidylinositol-3 kinase (PI3K)/AKT and mitogen-activated 
protein kinase (MAPK) pathways (Cobb et at., 1995; Venkateswarlu et at. , 2002) 
These pathways regulate cell cycle components at the level of transcription, 
mRNA stability, translation, post-translation modifications and protein stability (Lee 
et at. , 2000; Wang et at., 1999; Neve et al; 2002). 
Studies of the NRG1 protein heregulin, have demonstrated that autocrine 
heregulin activity involving activation of erb82 contributes to the growth of different 
types of cancer cells (Siamon et al. , 1987; Klapper et al., 2000). A study carried 
out by Venkateswarlu et at. (2002), examined heregulin and activated erbB2 
expression levels in a colon carcinoma (GEO) cell line in different phases of 
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growth in tissue culture. This study revealed constitutive activation of erb82 in the 
absence of exogenous growth factors or serum supplementation in GEO cells in 
the quiescent state. Blockade of erbB2 receptors with a heregulin neutralising 
antibody inhibited activation of erb82 receptor, confirming that endogenous 
heregulin expression was responsible for activating erb82 in quiescent cells. 
These growth arrested GEO cells were subsequently examined for constitutive 
activation of downstream signalling intermediates. Activation of P13K and MAPK 
pathways was analysed in growth arrested GEO celllysates by investigating 
expression of activated AKT, p70S6 and ERK1/2 by western blotting. Selective 
inhibitors to P13K and AKT and ERK1/2 were also utilized. The findings of this 
study revealed that activation of erb82 was the result of heregulin mediated 
interaction with erb83 and downstream activation of the ERK and PI3K/AKT 
pathways. Use of inhibitors confirmed that both the MAPK and PI3K pathways 
were crucial for re-entry of growth arrested GEO cells into the cell cycle. 
A study carried out by Hellyer et al. (2001 ) concluded that the erbB2/erbB3 
heregulin co-receptor couples to Pl3 kinase in a heregulin-dependant manner. 
The recruitment and activation of Pl3-kinase by the erb82/erb83 co-receptor 
occurs via its interaction with phosphorylated motifs at the c-terminus of erb83. 
Mutations within these motifs prevented erb83 binding the p85 regulatory or p110 
catalytic subunit of PI3K In fibroblasts, downstream signalling to the effector 
kinase AKT was dependant upon erb83 association with Pl3-kinase. Recruitment 
of P13-kinase to erbB3 was required for the lneregulin-dependant translocation of 
AKT to the plasma membrane for its subsequent activation. 
24 
Heregulin also activates matrix metalloproteases (MMP-9), which play an 
important role in tumour invasion and angiogenesis (Yao et al. , 2001 ; Breuleux, 
2007). Heregulin has also been shown to promote motility and invasiveness of 
cancer cells through regulation of autocrine motility factor expression (Talukder et 
al. , 2000) and enhances formation of lamellipodia, filopodia, and stress fibres 
which are accompanied by increase in cell migration (Adam et al. , 1998) through 
Pl3 kinase signalling. Pl3-kinase is involved in the proliferation, survival, adhesion 
and motility of tumour cells (Way et al., 2005; Breuleux., 2007). 
As well as the growth promoting effects, the neuregulin-1 proteins have also been 
shown to have a growth inhibitory effect (Xu et al. , 1997; Daly et al. , 1997; Le et 
al., 2000; Grimm et al., 1998; Weinstein et al., 1998; Le et al. , 2001 ). These 
effects include induction of apoptosis, differentiation and cell cycle arrest (Le et 
al., 2000, Le at al., 2002). Heregulin mediated apoptosis occurs through the 
caspase-9 mediated mitochondrial pathway and down regulation of Bcl-2 (a 
negative regulator of apoptosis) (Weinstein et al., 1998; Le et al., 2001 ). Several 
signalling molecules and pathways have been identified that relate to heregulin 
induced apoptosis which include, JNK pathway and mammalian target of 
rapamycin (mTOR) kinase and -p70S6k pathways (Le et al., 2002). The p70S6K 
are mitogen induced serine/threonine kinases that are involved in cell growth and 
survival (Avruch et al., 2001 ). The way in which different pathways interact to 
induce apoptosis is shown below in Figure 1.5. 
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Le et al. , 2002 
Figure 1.5: Pathways involved in heregulin induced apoptosis: Binding of the 
neuregulin-1 ligands results in receptor hetrodimerisation and tyrosine 
phosphorylation of Her-2 and Her-3. This creates docking sites for adaptor 
proteins and activates the downstream signalling pathways. Activation of caspase-
7 results in cleavage of PARP and apoptosis (HRG=heregulin, HER=human 
epidermal growth factor receptor) 
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In conclusion the NRG1 proteins are ligands that perform a wide range of 
context dependant functions. In my thesis I investigated the role of NRG1 in 
colorectal cancer. 
1.5 Aims 
The aims of this study were: 
• To investigate whether NRG11ies within the region of c8p12 frequently 
deleted in early colorectal tumours using fluorescent in-situ 
hybridisation and comparative genomic hybridisation. 
• To examine expression of the NRG1 protein and its receptor (Erb82) in 
tumours with and without LOH at c8p12 by immunohistochemistry. 
• To further characterise NRG1 protein expression using Western 
Blotting. 
• To investigate differences in protein cleavage by sequencing of the 
transmembrane domain in matched normal/tumour colorectal tumours. 
• To identify which alternative spliced NRG1 isoforms are expressed in 
matched normal/tumour colorectal samples. 
• To investigate mRNA expression levels of NRG1 isoforms in early and 
advanced colorectal tumours using quantitative real-time RT PCR. 
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Chapter 2 
Materials and Methods 
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2.1 LIST OF REAGENTS & SUPPLIERS 
Bioline, 16 Edge Business Centre, Humber Road london, NW2 6EW, U.K. 
10xNH4 buffer, Biotaq DNA polymerase, RQ1 Rnase-Free Dnase 
Amersham Pharmacia Biotech, Amersham Place, little Chalfont, 
Buckinghamshire, HP7 9NA, U.K. Deoxynucleoside triphosphate, ECL 
chemiluminescence detection, Ready-to -go-you Prime First strand beads 
Applied Biosystems, lingley House, 120 Birchwood Boulevard, Warrington, 
U.K. Real-time PCR master-mix, SYBR Green, SYBR green dye solution. 
BDH Ltd, Church Farm Business Park, Corston, Bath BA2 9AP,U.K. 
Bio-Rad detergent compatible assay, methanol, sodium citrate, sodium dodecyl 
sulphate (SDS), acetic acid. Boehringer Mannheim, Bell lane, lewes, East 
Sussex, BN71lG, U.K. Anti-avidin Cy-3, anti-dig FITC, 6-diamidine-2-
phenylindole (DAPI), dig blocking reagent, digioxigenin-11-UTP. 
Fisher Scientific UK ltd, Bishop Meadow Road, loughborough, 
leicestershire, lE11 5RG, U.K. Ethylenediaminetetraacetic acid (EDTA), 
formaldehyde, glycine, sodium chloride. Invitrogen ltd, 3Fountain Drive, 
lnchinnan Business Park, Paisley, PA4 9RF, U.K. Human Cot-1DNA New 
England Biolabs, 240 County Road, Ipswich, MA, U.K. 1 00 base pair DNA 
ladder. Promega Corporation, Delta House, Chilworth Science Park, 
Southampton, S016 7NS, U.K. 10xDnase buffer, Dnase I, random hexamers. 
GeneFiow, Fradley Business Centre, Wood End lane, Fradley, 
Staffordshire, WS13 8NF, U.K. Bisacrylamide bisulphate, protomarkers. Roche 
biochemicals, Hexagon Place, 6 Falcon Way, Welwyn Garden City, 
Hertfordshire, Al71TW, U.K. Biotin-16-dUTP, Biotin-nick-mix. Sigma-Aldrich 
Company ltd, The Old Brickyard, New Road, Gillingham, Dorset, SP8 4XT, 
U.K. Ammonium persulphate, 3-[N-morpholinol] propanesulfonic acid, butanol, 13-
mercaptoethanol, bovine serum albumin, bromophenol blue, chloramphenicol, 
diaminobenzidine tetrahydrochloride, ethanol, ethidium bromide, formamide, 
glucose, glycerol, guanidine hydrochloride, haematoxylin, hydrochloric acid, 
hydrogen peroxide, isopropanolol, L-B both, marvel, normal goat serum, phenol, 
phosphate buffered saline (PBS), potassium acetate, proteinase K, sodium 
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acetate, sodium hydroxide, strepavidin-peroxidase conjugate, 
tetramethylethylenediamine (Temed), Tris-HCL, Trizollysis buffer, Tween 20, 
urea, agarose. Vector Laboratories, ltd, 3 Accent Park, Bakewell Road 
Orton Southgate, Peterborough, PE2 6XS, U.K. Vector shield mounting 
solution. Alta Biosciences, University of Birmingham, Edgbaston, 
Birmingham, 815 2TH, U.K. Oligonucleotides. Qiagen House, Fleming Way, 
Crawley West, Sussex, RH10 9NQ, U.K. Qiagen PCR purification kit. Zymed 
Laboratories Inc, 561 Eccles Avenue, South San Francisco, CA, USA. 
Mouse anti-cytokeratin 8 antibody, anti-mouse lgG conjugated with horseradish 
peroxidase. Santa Cruz Insight Biotechnology ltd, PO Box 520, Wembley, 
Middlesex, HA9 7YN, U.K. HRG (C-20) rabbit polyclonal antibody, heregulin 
blocking peptide. DakoCytomation, Denmark House, Angel Drove, Ely, 
Cambridgeshire, CB7 4ET, U.K. HER2 {human epidermal growth factor receptor) 
rabbit anti-human antibody, goat anti-rabbit immunoglobulin conjugated with 
HRP. 
Cell lines used in this study 
All cell lines were purchase from American Tissue Type Culture (ATCC). 
H29 (Colon carcinoma}, HEK293 {Human embryonic kidney), Colo320 {Sigmoid 
colon carcinoma), Panc1 (Pancreatic ductal carcinoma), BxPC3 (Pancreatic 
carcinoma), HS578T (Breast normal tissue), HS174T (Colon adenocarcinoma), 
SW480 (Colon adenocarcinoma), Caco-2 (Polarized cell line), HCT116 
(Colorectal carcinoma), MCF-7 (Breast carcinoma). 
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2.2 PRIMER SEQUENCES 
Table 2.1: Primer sequence of the transmembrane domain. 
TM F' 
TM R' 
GGC AAG TGG AAG TGA CCT GT 
AGG CTG TGG AGC TCA GAT TC 
Table 2.2a: RT-PCR primer sequences used for NRG1 isoform analysis 
Primer Primer Sequence 5' -3' Annealing Product size 
temperature 
All CAG TAT CCA CAG AAG GAG CAA AT 
CTC GAG GGG m GAA AGG T 
56 150bp 
Gamma GAG TAT CCA CAG AAG GAG CAA AT 
A(.K~ A(.;T (.;AT (.;Ar. (.;AA Tr-.c:; T(.; 
56 333bp 
Beta1 GTG CCC AAA TGA GTT TAC TGG 56 174bp 
TAG GCC ACC ACA CACATG AT 
GGF2 GAG GCT CAA GGA GGACAG C 56 236bp 
AAC TGG m CAC ACC GAA GG 
Beta 3 TAC ATC CAC CAC TGG GACAA 
CCA ACT AGTCGC GAA CAG AG 
56 379bp 
SMDF CCG ACA CCG AAG AA T CGT AT 56 238bp 
TCT CCT TCT CCG CAC A TT TT 
Alpha CTG AGA ATG TGC CCA TGA AA 57 367bp 
GAA TGA TGG GCT GTG GAA GT 
ndf43 GAG GCC CTC GTG AA T GTA AC 56 156bp 
TTG CTG ATA GCT GGA TCT GC 
3 1 
Table 2.2b: 8-actin primer sequence 
Primer Primer sequence 5' -3' Annealing Product 
Temperature oc size 
B-act in ACA TCC GCA AAG ACC TGT AC 55 223bp 
ATA CTC CTG CTT GCT AAT CC 
Table 2.3: Real-Time Primer Sequences used for NRG1 isoform analysis 
Primer Primer Sequence 5' -3' Product 
~i7A 
Gamma GGT TTT CIT GGT TGG TT A TTC AGA A 103bp 
TCT TAC AGC TTA ATT CAT ACA TTG GAT GT 
Beta-1 ACG T AA TGG CCA GCT TCT ACA AG 124bp 
CAC ATG ATG CCG ACC ACA AG 
Beta -3 TCC ATC TTC TTT ATA CAA TGA CCA CAT 87bp 
AA T TAA CTT ACC ATC ATT TCA AGT GCA 
ndf -43 AGG AGG CCC TCG TGA ATG T AA 135bp 
CAT TTG GAT CTG TGT GCC TTG T 
KRT8 GAT CGC CAC CTA CAG GAA GCT 100bp 
ACT CAT GTT CTG CAT CCC AGA CT 
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2.3 Extraction of RNA, DNA and protein 
Isolation of RNA, DNA and protein from colorectal tissue samples and cell lines 
was carried out using TRI reagent as per manufacturers instructions. 
Colorectal tissue samples were homogenised in 1 ml of cold TRI reagent buffer 
and the samples were transferred to liquid nitrogen for subsequent triple 
extraction. Cells in 25cm2 flasks were lysed using 0.5ml of TRI reagent buffer. 
Cells were left to lyse for 5 mins and were then transferred to a sterile tube and 
stored at -80°C. 
2.3.1 Isolation of RNA 
Colm·ectal tissue and cell line homogenates in TRI reagent buffer were thawed at 
room temperature (RT). 0.2ml of chloroform was added to each sample, mixed 
vigorously and stored at RT for 15 mins. All of the samples were centrifuged at 
12,000g for 15 mins at 4°C separating the solution into organic phase, interphase 
and aqueous phase. 
To precipitate RNA, the aqueous phase was transferred in to separate fresh 
tubes and 0.5ml of isopropanol was added to each tube. Samples were stored at 
RT for 10 mins and then centrifuged at 12,000g for 8 mins at 4°. The supernatant 
was removed and RNA pellet was washed with 75% ethanol, then centrifuged at 
7500g for 5 mins at 4°C. The ethanol was removed and the RNA pellet was air-
dried and resuspended in 30f..ll of distilled water. RNA was stored at -aooc for 
subsequent use. 
33 
2.3.2 Extraction of DNA 
DNA was recovered from the interphase and organic phase using ethanol. O.Sml 
of ethanol was added to each tube and samples mixed by inversion and 
incubated at RT for 3 mins then centrifuged at 2000g for 5 mins at 4°C. The 
phenol-ethanol supernatant was transferred to a fresh tube, and stored at 4°C. 
The DNA pellet was washed twice in 1 ml of 0.1 M sodium citrate in 10% ethanol 
(10ml of 1M sodium citrate, 10ml of ethanol, 80ml of H20). During each wash the 
samples were stored at RT for 30 mins, with periodic mixing and then centrifuged 
at 2000g for 5 mins at 4°C. The DNA pellet was washed in 75% ethanol for 10-20 
mins at RT, and centrifuged at 2000g for 5 mins at 4°C. The ethanol wash was 
removed and the DNA pellet was air dried at RT. Finally, the DNA pellet was 
resuspended in 8mM NaOH. 
2.3.3 Protein extraction 
Protein was precipitated from the phenol-ethanol supernatant with isopropanol. 
8001JI of isopropanol was added to each tube and samples were incubated at RT 
for 1Om ins then centrifuged at 4°C at 12000g for 1Om ins. The supernatant was 
discarded and protein pellet was taken through a series of 3 washes in 1 ml of 
0.3M guanidine hydrochloride in 95% ethanol for 20 mins at RT and centrifuged 
at 7500g for 5 mins at 4°C. The protein pellet was resuspended in 2ml of 100% 
ethanol, incubated at RT for 20 mins and centrifuged at 7500g for 5 mins at 4°C. 
The ethanol wash was removed and the pellet was air-dried and dissolved in 
1 OOul of 6M urea. Samples were stored at RT overnight to allow protein 
solubilisation. 
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2.3.4 Extraction of DNA using proteinase K 
DNA from matched normal/tumour colorectal samples was extracted using 
proteinase K and used in comparative genomic hybridisation and sequencing 
reactions. 0.5ml of DNA digestion buffer (50mM Tris-HCL pH8.0; 1 OOmM EDTA 
pH8.0; 100mM NaCI ; 1% SDS) with 0.5mg/ml proteinase K, was added to a 
small section of frozen tissue and samples were incubated overnight at 37°C. 
The samples were rotated overnight to allow mechanical agitation to aid in 
disruption of the tissues. 0. 7 ml of phenol was added to the samples which were 
then centrifuged at 12000g for 5 mins. The upper phase (0.5ml) was recovered 
and 0. 7 ml of chloroform was added. The samples were mixed and centrifuged for 
a further 5 mins and the aqueous phase removed. 1ml of 100% ethanol was 
added and the samples were mixed by inversion. Samples were microfuged for 5 
mins at 13 OOOg and the supernatant was carefully removed and discarded. 0.5ml 
- 1 ml of 70% ethanol was added to the samples and microfuged for 5 mins at 13 
OOOg after which the supernatant was carefully removed and discarded. The 
samples were air dried and DNA was resuspended in 1 00 - 200 1-JI of TE buffer. 
2.4 Isolation of DNA from bacterial artificial chromosome clones 
Clones were streaked on to agar containing 251-Jg/ml of chloramphenicol and 
grown overnight at 37° C. 5ml of autoclaved LB broth containing 25fJg/ml of 
chloramphenicol was inoculated with a single colony and incubated overnight at 
37°C in a shaker to provide constant agitation. The overnight culture was 
centrifuged at 1 ,500g for 10 mins following which the LB broth was discarded and 
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the pellet was resuspended in 200~1 of lysis buffer (10mM Tris pH 8.0, 25mM 
EDTA pH 8.0, SOmM Glucose} and incubated on ice for 5mins. 400~1 of a freshly 
prepared solution of 0.2M NaOH, 1% sodium dodecyl sulphate, was added. The 
contents were mixed gently by inversion and incubated on ice for a further 5 mins. 
300~1 of prechilled 3M potassium acetate was added and the contents mixed 
gently by inversion and placed at -80°C for 30 mins. The suspension was 
allowed to thaw following which it was centrifuged at 13,000rpm for 15 mins to 
collect cell debris and precipitated salts. The resulting supernatant was 
transferred to a fresh tube and 0.6 volumes of isopropanol was added and 
contents mixed by inversion and left to precipitate at RT for 1 0 mins. The 
contents were centrifuged at 13,000 rpm for 15 mins to pellet the DNA The 
supernatant was discarded and the DNA pellet washed was with 1 ml of 70% 
ethanol and centrifuged at 13,000 rpm for 2 mins. Following centrifugation the 
ethanol was removed and the DNA pellet was dried and resuspended in 40~1 of 
TE pH 8.0 (50mM Tris, 50mM EDTA} overnight. Finally 1~1 of 10~g/ml of RNAse 
A was added and samples were incubated at 37°C for 1 hour. The DNA was 
stored at -20°C. 
2.5 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to resolve DNA, reverse-transcriptase and 
real-time PCR products. The agarose gels were made to a concentration of 1-
3%, depending on the size of fragments to be resolved in 1 OOml of 1 x TAE buffer 
pH 7.8 (Final working buffer concentration (1X}: 40mM Tris acetate, 1 mM EDTA} 
Tris base, EDTA, NaOH} and 0.01mg/ml ethidium bromide. The type of comb 
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used to cast the wells depended on the number and volume of samples. The gel 
was allowed to set for 1 hour after which it was immersed in a gel tank containing 
enough running buffer (the same used for casting the gel) to cover the gel. Prior 
to loading the wells, 1 ul of loading dye (6X Loading dye 15% w/v Ficoll 400, 
0.025% w/v Bromophenol Blue, 0.025% w/v Xylene Cyanol) was added to 5J.JI of 
each sample. 0.51-Jg of molecular weight marker 1 OObp DNA ladder was also run 
alongside the samples. The gel was run at 1 OOV for approximately 40 mins and 
photographed on a UV transilluminator. 
2.6 Quantification of RNA, DNA and protein 
2.6.1 Quality and quantity of extracted RNA 
Formaldehyde gel electrophoresis and spectophotometry were used to determine 
the quality and quantity of extracted total RNA respectively. 
RNA quality 
This was determined by Northern gel electrophoresis. A 50 ml formaldehyde gel 
(0.75g agarose, 37 ml H20 and 5 ml of 10x MOPS buffer (0.2 M MOPS (3-
[N_morpholinol) propanesulfonic acid, O.OSM sodium acetate, 0.01 M EDT A. 
made up to pH 7.0 with 1M NaOH) was made. The gel was melted and allowed 
to cool to 50 oc prior to adding 8ml of 37% formaldehyde, The gel was placed in a 
tank with 1 X MOPS but was not fully submerged. 
5 J.JI of RNA (1 IJ.g) was added to 15 J.JI of loading buffer (0.72 ml Formamide, 0.16 
ml10 X MOPS buffer, 0.26 ml Formaldehyde (37%), 0.08 ml Bromophenol blue 
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(saturated solution), 0.18 ml H20 , 0.10 ml 80% glycerol) and heated to 60° C for 5 
m ins and placed on ice. The gel was loaded and run at 80 to 1 00 volts. The gel 
was washed in 10% glycine for 20 mins after which 100 ~I of 10 mg/ml ethidium 
bromide was added per 250 ml of glycine and the gel was incubated for a further 
10 mins. The gel was destained in H20 for 2 X 20 mins and 10X SSC (1 .5M 
NaCI, 0.15 M Na3 Citrate, adjusted to pH 7.0 with 1 M HCL) for a further 20 mins, 
and photographed. 
Quantitation of RNA 
A spectophotometer was used to quantify the amount of RNA present in the 
samples. The absorbance of RNA was measured at wavelengths of 260 and 
280nm using a quartz cuvette. The absorbance reading at 260nm allows for the 
calculation of the concentration of nucleic acids in the sample. An absorbance of 
one unit at 260 nm corresponds to 40 1..1g of RNA per ml (A260 =1= 40 I.Jg/ml). 
The ratio of A260/A280 provides an assessment of the purity of the nucleic acid. 
To calculate the RNA concentration the following calculation was used: 
RNA cone ug/ml = A260 x 40 X dilution factor. 
2.6.2 DNA quantification and Quality 
DNA quality 
The quality of the extracted DNA was assessed by direct analysis of 0.51Jg of 
DNA on a 1% agarose gel. 
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DNA quantitation 
Spectrophotometery was used to quantify the amount of DNA extracted. 
Spectrophotometer readings were taken at wavelengths 260nm and 280nm. The 
260nm reading allowed the concentration of DNA to be calculated and an OD 
reading of one corresponds to approximately 50 J.Jg/ml for double-stranded DNA. 
The DNA quality measurement is based on the fact that OD at 260 nm is twice 
that at 280 nm if the solution contains pure DNA. Clean DNA has an OD-
260/0D280 between 1.8 and 2.0. DNA was quantitated using the following 
calculation: 
DNA cone ug/ml: A260 x 50 X dilution factor. 
2.6.3 Protein Quantification 
Protein concentration was determined using the Bio-Rad detergent compatible 
assay. Depending on the volume of protein this assay can be adapted to 
determine high (0.2-1 .5mg/ml) and low (5-250J.Jg/ml) concentrations of proteins. 
Bovine serum albumin (BSA) was used as a control to plot a standard curve for 
Bio-Rad protein assay. The BSA was dissolved in 6M urea (1mg/ml) and serial 
dilutions were carried out. In brief, a 1 0-step two-fold dilution series of BSA was 
carried out in a 96 well microplate and used as controls. 
1 OJJI aliquots of protein samples were distributed into further wells on the plate 
and 2001JI of Bio-Rad DC mix (Reagent A and B) at a dilution of 1 :5 respectively 
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was added to each well. A blue colour change indicated the presence of protein in 
the samples. 
The absorbance was measured at 595nm using a microplate reader and a 
standard curve of absorbance vs. BSA concentration (mg/ml) was plotted to 
determine protein concentrations of the colorectal samples. 
2. 7 eDNA synthesis 
First strand eDNA synthesis was carried out using 1 ug of RNA following DNase 
digestion. 1 J.JI of 1 0 x DNase buffer and 1 ~I RQ 1 Rnase-F ree DNase ( 1 unit) was 
added to 1 J.J9 of RNA in a fresh tube the solution was mixed and incubated at RT 
for 15 mins. The reaction was terminated by adding 1 J.JI of Stop solution (25mM 
EDT A pH 8. 0) and incubating at 65° C for 15 mins. 
22J.JI of DEPC - treated H20 was added to DNase -treated RNA and incubated at 
65°C for 1 0 mins. The samples were placed in ice for 2 mins following which the 
contents were transferred to a fresh tube containing ready-to-go-you Prime First 
strand beads. 1 J.JI of random hexamers was added to the tube and samples were 
incubated at RT for 1 minute. The samples were vortexed, centrifuged and 
incubated at 37°C for 1 hour. The eDNA produced was stored at -20°C. 
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2.8 Fluorescent in-situ hybridisation 
2.8.1 Probe labelling 
Probes were labelled by nick translation. Centromeric probes (D8Z2, C8 
centromeric probe) were labelled with digioxigenin-11-UTP and probes to the 
region of interest (NRG1) were labelled with biotin-16-dUTP. Probe DNA (5.5ug, 
3ul) was nick translated with 4ul digoxin or biotin-nick mix stabilized reaction 
buffer (50% glycerol and DNase polymerase 1, DNase 1, 0.25 mM dATP, 0.25 
mM dCTP, 0.25 mM dGTP, 0.25 mM dTIP and 0.08 mM Biotin-16-
dUTP/digioxigenin-11-UTP). The reaction was made up to a final volume of 19J,JI 
with distilled H20, mixed, centrifuged briefly and incubated for 90 mins at 15°C. 
The reaction was terminated by adding 1J,JI of0.5 M EDTA (pH 8.0) and 
incubating at 65°C for 1 0 mins. 
2.8.2 Preparation of touch-prep and lymphocyte metaphase spreads 
To prepare touch-prep slides a small piece of tumour tissue was cut from the 
frozen tumour sample, thawed and blotted on Whatman 3MM paper before 
touching onto a polylysine coated slides. The slides were immediately fixed in 
methanol: acetic acid (3:1) for 20 mins, air-dried and stored at -20°C. 
Lymphocyte metaphase spreads 
Cultured lymphocyte suspension (gift from Genetic Unit, Birmingham Womens 
Hospital NHS Trust) was placed on to a slide and allowed to air dry prior to 
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fixation with freshly prepared (3:1) methanol: acetic acid for 20 mins. Slides were 
air dried and stored at 20°C until used. 
2.8.3 Pre-treatmemt of slides 
Slides were pre-treated prior to hybridisation by washing in 3:1 methanol and 
acetic acid for 5 mins, followed by 2xSSC (0.3M sodium chloride, 0.03M sodium 
citrate) for 10 mins. Slides were incubated in 0.01% pepsin solution (0.01g 
pepsin in 1M HCL) at 37°C for 10 mins, washed in 4% paraformaldehyde for 5 
mins then in distilled H20 for 5 mins and allowed to air-dry. Slides were 
denatured in 70% formamide at aooc for 5 mins, dehydrated in 70%, 85% and 
100% cold ethanol series for 2 mins each and allowed to air-dry. 
2.8.4 Hybridisation 
The hybridisation mix consisted of 14J .. d of mastermix ( 5ml of deionised 
formamide: (200ml formamide, 10g mixed resin beads); 1 ml of 20x SSC: (3M 
sodium chloride (175.2g/l), 0.3M sodium citrate (88.2g/l); 1g of dextran sulphate 
and 71JI of dH20) 5.51-Jg (31JI) of labelled probe, specific to the region of interest 
(NRG1 gene), 11Jg (2JJI) of labelled centromeric (D8Z2) probe and 11JI of human 
Cot-1 DNA. The hybridisation mix was denatured at oooc for 5 mins and then 
incubated at 37°C for 15 mins. The pre-treated slides were placed on a hot block 
at 37°C and 301-JI of hybridisation mix was added, a coverslip was placed over 
and sealed with rubber solution. The slides were incubated in a moist chamber at 
37°C overnight. 
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2.8.5 Detection of probes 
The coverslips were gently removed from the slides which were taken through a 
series of post hybridisation washes at 45°e in 50% formamide for 5 mins x 3, 
twice in 2 X SSe, once in 4 X SSe, 0.05% Tween 20 (200ml of 20x SSe, 800ml 
dH20 , O.Sml Tween 20) and finally in 4 x SSe, 0.05% Tween 20 for 5mins at RT. 
To detect biotin labelled probes slides were incubated with 1001-JI of anti-avidin 
ey3 in blocking reagent (final working concentration: 
0.251-JI of 2mg/ml stock of anti-avidin ey3 in 99.751-JI of blocking reagent : 500ml 
of 4 X sse, 0.05% Tween 20, 25g non-fat milk powder) under parafilm for 20 
mins at 37°e. Slides were then washed 3 times in 4 x sse, 0.05% Tween 20 for 
5 mins each. 
To detect the digoxygenin probes slides were incubated with 1 OO!JI of anti-
digoxygenin conjugated to FITe in blocking solution (final working concentration: 
dilute 51JI of anti- digoxygenin conjugated to FITe in 2001-JI of digoxygenin 
blocking reagent: 4 x sse, 0.05% Tween 20, 0.5% dig blocking reagent) under 
parafilm at 37oe for 20 mins. Slides were taken through a further series of 
washes as described previously and were counterstained in 4, 6-diamidine-2-
phenylindole (DAPI; 0.51-Jg/ml) in vector shield mounting solution prior to 
microscopy. 
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2.8.6 Image analysis and quantification 
Slides were examined under a fluorescent microscope using Smart Capture 
software. For each tumour sample, 1 00 tumour cell nuclei were identified and 
scored for both Cy3 (NRG1) and FITC (8 centromere) signal. Deletion was 
defined as cells, which had fewer Cy3 signals than FITC signals. Cells, which 
appeared intact and were not overlapping, were counted. In order to limit false 
positives, cells with no FITC signal were discarded for deletion scoring. 
2.9 Comparative genomic hybridisation (CGH) 
This work was carried out in collaboration with Dr P.Edwards (Cambridge MRC 
centre). DNA from matched normal/tumour samples was sent to the MRC centre 
in Cambridge for CGH analysis. The method employed for CGH has been 
described by Huang et al. (2004). 
DNA extracted from tumour samples (Proteinase-K) and normal reference DNA 
were differentially labelled with fluorescent dyes and co-hybridised in equal 
amounts to normal metaphase spreads. The difference in fluorescence intensity 
that reflects the ratio of tumour DNA to control DNA hybridised to chromosomal 
spread were measured using digital imaging and software analysis to determine 
fluorescence values. The amplification and deletion of specific chromosome 
regions were detected by the increased and decreased ratios of tumour specific 
fluorescence to control respectively. 
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2.10 Immunohistochemistry 
Paraffin tissue sections/slides were dewaxed in xylene for 5 mins and rehydrated 
in ethanol series (100% ethanol x 2, 70% ethanol x1 for 5 mins each). Slides 
were then taken through a series of three washes in phosphate buffered saline 
(PBS) for 5 mins each. Slides and cells mounted on coverslips were blocked with 
hydrogen peroxide in methanol (15ml of 30% hydrogen peroxide in 500ml of 
methanol) for 15 mins and then further washes with PBS were carried out as 
described above. Slides and coverslips were blocked with 1 0% normal goat 
serum for 30 mins and then incubated with the primary antibody of appropriate 
concentration in 10% normal goat serum overnight at 4°C. A further 3 washes 
with PBS were carried out, after which sections and coverslips were incubated 
with biotinylated secondary antibody of appropriate concentration for one hour. 
Serial PBS washes were performed and the sections were incubated for 30 mins 
with streptavidin-peroxidase conjugate before incubation with diaminobenzidine 
tetrahydrochloride. Finally, further serial PBS washes were carried out after 
which sections and coverslips were counterstained with haematoxylin, 
dehydrated in ethanol series (70% ethanol x1 , 100% ethanol x 2 for 5 mins each) 
and fixed in xylene for 5 mins. Slides and coverslips were mounted using non-
aqueous permanent mounting medium and a coverslip was placed. The primary 
and secondary antibody concentrations were titrated until good staining with little 
or no background was achieved with a primary antibody concentration of 1 :200 
and a secondary antibody concentration of 1 :500. The heregulin blocking peptide 
was used as a control. The blocking peptide was prepared as per manufacturers 
instructions. 1l-JI of primary antibody was added to a five-fold excess of blocking 
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peptide (11JQ /Sui) in a small volume (501JI) of PBS for neutralisation. The antibody 
/blocking peptide mixture was incubated at RT for 2 hours following which the 
mixture was diluted in a 1501JI of PBS for use. 
Slides were analysed by light microscopy. The intensity of staining and the 
proportion of positively stained tumour cells were scored. lmmunoreaction was 
determined as: 1 + weak staining, 2+ moderate staining and 3+ strong staining 
patterns. The proportion of tumour stained was divided in to 4 categories, 0-10%, 
10-25%, 25-50%, 50-75% and > 75% tumour stained. 
Slides were scored by a second independent observer (T. Philippe). 
2.11 Immunocytochemical staining: HercepTest™ 
The HercepTest assay was used to investigate ErbB -2 overexpression. This 
work was carried out in collaboration with Dr.P.Taniere (Pathology Department, 
University Hospital Birmingham). 
Paraffin sections were dewaxed in xylene for Smins and rehydrated in ethanol 
series (100% ethanol x 2, 95% ethanol x2 for 4 mins each). 
Slides were placed in distilled water for a minimum of 30 sees and were then 
immersed in preheated epitope retrieval solution (0.1 moi/L citrate buffer with an 
antimicrobial agent) and incubated in a water bath at 95-99°C for 40 mins. 
Slides were removed and allowed to cool at RT for 20mins and were then rinsed 
in wash buffer (x1 OTris/HCL buffer working dilution 1:1 0) 
and blocked with 200ul of peroxidase -blocking reagent (3% hydrogen peroxide 
containing 15mmoi/L sodium azide) for 5 mins. Slides were then rinsed in wash 
buffer, and incubated with 200ul of primary Anti-HER2 protein antibody (or 
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negative control reagent- immunoglobulin fraction of normal rabbit serum at an 
equivalent protein concentration as the antibody to HER2 protein) for 30 mins. 
Following incubation, slides were rinsed and incubated with 200ul of visualization 
reagent (dextran polymer conjugated with HRP and affinity-isolated goat anti-
rabbit immunoglobulins in Tris/HCL buffer containing stabilising protein and an 
antimicrobial agent) for 30 mins. Slides were rinsed in wash buffer x2 and 
incubated in diaminobenzidine tetrahydrochloride (DAB) for 10 mins, rinsed with 
deionised water and counterstained in a bath of haematoxylin for 2-5 mins. 
Residual haematoxylin was removed by gently rinsing the slides in a distilled 
water bath for 2-5 mins. All slides were mounted with non-aqueous, permanent 
mounting medium prior to viewing. 
Slides were analysed using light microscopy and scored using the HercepTest 
guidelines. Sections of breast carcinoma known to be strongly, moderate and 
weakly positive for erbB-2 receptors were used as controls. The Hercep Test was 
reported as being negative if no membrane staining was observed or <1 0% of 
tumour cells were stained (score 0) and if faint staining was noted in only part of 
the membrane of >1 0% of tumour cells (score 1 + ). A positive Hercep Test for 
erbB2 overexpression was reported when >10% of tumour cells had weak to 
moderate complete membrane staining (score 2+) and if strong complete 
membrane staining was noted in >10% of tumour cells (score 3+). Slides were 
scored by a second independent observer (T. Philippe). 
Tumour samples were excluded from further analysis if staining artefacts were 
noted and if tissue sections on slides were incomplete and therefore not 
interpretable. 
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2.12 Multiple Tissue array (MTA) construction 
A multiple tissue array was used to investigate heregulin expression and erb82 
overexpression in a large cohort of colorectal tumours. The MT A was constructed 
at the Pathology Department (Queen Elizabeth Hospital, University of 
Bimingham, NHS Trust) and contained 250 paraffin embedded colorectal 
tumours. All tumour samples were collected according to local ethical guidelines. 
For the purpose of this study, permission was obtained to use the tissue array. 
Each slide contained sections of 20 different tumour samples as shown in Figure 
2.1 below. 
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Figure 2.1 :Multiple Tissue Array Key. The above figure illustrates the orientation 
of colorectal tumours samples in each section. Liver tissue was used to orientate 
the slides. 
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In order to take into account tissue fixation and variation in reproducibility of 
immunohistochemical data, four slides containing the same group of 20 tumours 
( eg 1 A, 1 B, 1 C, 1 D) were obtained in which each of the individual tumour sample 
were embedded at different locations. Liver tissue (a positive control for 
heregulin expression) was used to help with orientation of the slides. A replicate 
tissue array was obtained so that the same sections were used to investigate 
heregulin expression and Erb82 overexpression. 
2.12.1 Clinical and pathological data 
Clinical and pathological data were collected in accordance with ethical 
guidelines. Tumour grade, stage, lymph node involvement and evidence of 
metastases were collected. The array was constructed with tumour sections from 
patients who had undergone surgical resection between June 1997 and Feb 
2002. Follow up data was collected till June 2005. 
2.13 Western Blotting 
A separating gel (1 .5M Tris pH 8.8, 4.0ml of bisacrylamide bisulphate, 1 OOul of 
10% sodium doceyl sulphate (SDS), SOul of 10% ammonium persulphate, 3.4ml 
of distilled H20 and 1 Oul of 99% T emed) was made and poured between two 
BIORAD mini gels plates. The top surface of the gel was covered with water 
saturated butanol and allowed to set at RT for 1 hour. Once the gel had set, the 
water saturated butanol layer was poured off, and the top surface of the gel was 
rinsed with distilled Hi). A stacking gel was made (6.1 ml of dHi), 2.5ml 
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bisacrylamide (37.5:1 ), 1.5ml of 0.5M Tris pH 6.8, 100ul of 10% SDS, SOul of 
1 0% ammonium persulphate and 1 Oul of 99% T emed) and poured on top of the 
separating gel. A comb was placed between the two glass plates. The size of 
comb used depended on the number and volume of the samples. The gel was 
allowed to set for 40 mins. 
Celllysates and colorectal protein samples were prepared by adding 
2 x SDS-PAGE sample buffer (1.0 ml of 0.5 M Tris pH 6.8, 0.8ml of Glycerol, 
1.6ml of 10% SDS, 0.4ml of 8-mercaptoethanol and 0.2ml of bromophenol blue). 
Prior to loading the samples were boiled for 5 mins to denature the protein. The 
gel was placed in a tank containing 1x SDS-PAGE buffer (3g Tris, 14.4g Glycine, 
1 g sodium doceyl sulphate/L). 20~g of protein was loaded in to each well and 51JI 
of protein marker (ProtoMarkers) was run alongside the protein samples. The gel 
was run at 1 OOV until the tracking dye had just run off the geL The stacking gel 
was removed and the separating gel was used for transfer. 
2.13.1 Transfer 
Hybond ECL Nitrocellulose membrane, sponge pads and 3MM Whatman paper 
were soaked in Towbin transfer buffer (3.03gll of 25mM Tris, 14.4g/l of 192mM 
glycine and 200m Ill of 20% methanol) for 10 mins to allow equilibration of the 
membrane. A sandwich consisting of sponge pad, 3MM Whatman, nitrocellulose 
membrane, separating gel, 3MM Whatman paper and sponge pad was made and 
placed in an electroblotting cassette. The Hybond ECL nitrocellulose membrane 
was placed on the anode side of the gel to allow transfer of proteins from gel to 
nitrocellulose membrane Transfer was carried being running at 11 OV for 90 mins. 
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Following transfer the membrane the orientation of the gel was marked on the 
membrane. 
2.13.2 Optimisation of antibodies for Western blotting 
A range of primary and secondary antibody dilutions were used to optimise the 
antibody concentration for Western Blot analysis. The primary and secondary 
antibody concentrations were titrated until bands with little or no background 
staining were achieved. Following transfer, the nitrocellulose membrane was 
incubated in 4% Marvel in 1xTBST (10mM Tris pH 8, 0.15M NaCI and 0.05% 
Tween 20) for 1 hour to block non-specific binding and reduce background 
staining. The membrane was incubated with primary antibody (diluted in 2% 
Marvel in 1 x TBST) of appropriate concentration overnight and taken through a 
series of 3 washes in 1 x TBST for 5 mins each. The nitrocellulose membrane was 
incubated with the secondary antibody (diluted in 2% Marvel in 1 x TBST) for 1 
hour. Finally, further washes in 1 x TBST was carried out as described previously. 
Primary and secondary antibody concentrations of 1:500 and 1:50,000 were used 
respectively for Western Blotting. The heregulin blocking peptide was prepared 
as per manufacturers instructions. 11-11 of primary antibody was added to a five-
fold excess of blocking peptide (11Jg /5ul) in a small volume (501JI) of PBS for 
neutralisation. The antibody /blocking peptide mixture was incubated at RT for 2 
hours following which the mixture was diluted in a 1 ml of PBS for Western blot 
analysis. 
To check for protein loading the membranes were repro bed with cytokeratin 8 
antibody. Cytokeratin 8 is present in simple epithelial cells and 
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adenocarcinomas. It is not expressed in squamous epithelia and is a basic type 11 
cytokeratin with a molecular weight of - 52kDa. A monoclonal mouse anti-
cytokeratin 8 primary antibody (1 :200 dilution) and anti-mouse lgG conjugated 
with HRP was used as a secondary antibody (1 :1000 dilution). Blots were taken 
through a series of three washes in 1xTBST for 5 mins each and then incubated 
in primary cytokeratin 8 antibody (diluted in 2% Marval in 1xTBST) for 1hour at 
RT. The blot was then taken through a further 3 washes in 1 x TBST and then 
incubated with secondary antibody for 1 hour at RT. Finally, further washes in 1x 
TBST was carried out as described previously. 
2.13.3 Detection of protein 
The protein was detected using the ECL chemiluminescent detection method. 
Equal quantities of ECL detection reagents A and B were mixed and poured into 
a petri dish. The membrane was placed into the petri dish (protein side down) 
and covered with the ECL mix for 1 min. The blots were then Saran wrapped, and 
placed protein side up in an x-ray cassette where multiple exposures of 
autoradiography film was carried out to obtain the best image. 
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2.14 Antibodies used 
Primary antibodies: 
• HRG (C-20) rabbit polyclonal antibody (Santa Cruz Biotechnology Inc), 
[cone used for immunohistochemistry 1 :200; cone for Western 1 :500] 
• HER2 (human epidermal growth factor receptor) rabbit anti-human 
antibody (DakoCytomation California Inc). 
• Anti-cytokeratin 8 mouse monoclonal antibody (Zymed Labs, Ca) 
[cone for Western 1 :200] 
Blocking peptide: 
• Heregulin blocking peptide (Santa Cruz Biotechnology Inc), 
[1 OO~g peptide in O.Sml PBS containing 0.1% sodium azide and 1 OO~g 
BSA] 
Secondary antibodies: 
• Anti-rabbit lgG antibody (Sigma) conjugated to horse radish peroxidase 
(HRP) (cone used for Western 1 :50000] 
• Goat anti-rabbit immunoglobulin conjugated with horseradish peroxidase 
(DakoCytomation California Inc) 
[cone used for immunohistochemistry 1 :500] 
• Anti-mouse lgG conjugated with horseradish peroxidase 
[cone used for immunohistochemistry 1 : 1 000] 
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2.15 Sequencing of transmembrane domain 
Optimisation and design of transmembrane primer 
Primers were designed (using the Primer 3 output programme across the 
intronlexon boundary that encompassed the whole of the transmembrane domain 
sequence. The forward and reverse primer sequences were put through a Blast 
search to ensure that each sequence was specific to the gene of interest. 
Reactions were optimised using DNA from human embryonic kidney (HEK 293) 
cell lines. PCR conditions were: 94°C for 2m ins, 35 cycles of 94°C for 10 sec, 
60°C for 20 sec, 72°C for 30sec followed by a final elongation step of 72oC for 
Smin. The tumour samples selected for sequencing of the transmembrane 
domain are shown in Table 2.4 below. 
Sample No Histology Deletion status 
33 Advanced tumour T 4N1 MO Deletion 
38 Advanced tumour T 4NOMO Deletion 
65 Advanced tumour T3NOM1 No deletion 
66 Advanced tumour T3N2M1 No deletion 
Table 2.4: Clinicopathological and deletion status of tumour samples used 
for sequencing of transmembrane domain 
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DNA was extracted from the above tumours using Tri reagent as previously 
described. 
Reverse transcriptase-PCR (RT -PCR) with the transmembrane primers on 
matched colorectal normal/tumour samples 
In order to sequence the transmembrane domain of the above matched 
normal/tumour samples, the region of interest was amplified by RT-PCR using 
primers that flanked the transmembrane domain (shown in Table 2.1). eDNA 
from the human embryonic kidney cell line HEK 293 was used as a positive 
control and distilled H:z() as a negative control. 
All of the PCR products were resolved on an agarose gel. Sui of the PCR product 
was run alongside 0.5ug of 100 bp DNA ladder on an agarose gel. The gel was 
photographed on a UV transilluminator using Polaroid film (Sigma) with exposure 
time of 1 sec. 
Sequencing of the transmembrane domain 
For this purpose the QIAquick PCR purification protocol was used. 5 volumes of 
buffer PB was added to 1 volume of PCR sample and mixed. To bind DNA, the 
sample was applied to the QIAquick column and centrifuged for 30-60secs in a 
microcentrifuge at 13,000rpm. The flow-through was discarded and the QIAquick 
column was placed back in 2ml collection tube. To wash, 0.75ml of buffer PE was 
added to the QIAquick column and centrifuged for 30-60 sees. The flow-through 
was discarded and the column was placed back in the collection tube and 
centrifuged for an additional 1 minute. The QIAquick column was then placed in a 
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clean tube and SOul of buffer EB (10mM Tris-CI, pH 8.5) was added to the column 
and centrifuged for 1 min to elute the DNA. 
Sui of each sample was run on an agarose gel to check the yield of DNA and to 
ensure that the product was clean. 
To sequence a 200-SOObp product, 3-10ng of DNA template was required. 
For each sample the amount of DNA present was estimated by comparing the 
intensity of gel bands against molecular weight markers. Each sample was taken 
through a PCR reaction using the Big Dye Cycle sequencing kit. Each reaction 
contained, 2ul of the terminator ready reaction mix, 6ul of dilution buffer (200mM 
Tris-HCL (pH 9), 5mM MgCb), 1ul of 5pmole primer and appropriate volume of 
DNA template for each sample. The final volume was made up to 20ul with 
distilled water. For each sample the reaction was carried out with both the 
forward and reverse primer sequence. The PCR products of the sequencing 
reaction were purified (Big Dye Version 3) and sequenced at the Functional 
Genomics Unit (University of Birmingham). 
The sequencing data obtained for each fragment sequence was put through a 
Blast search (NCBI website). The sequencing data obtained for each matched 
normal/tumour sample was analysed. The sequence data was checked to ensure 
that each peak seen corresponded to the correct nucleotide sequence. 
2.16 lsoform- specific reverse transciptase polymerase chain reaction 
(RT- PCR) 
All PCR reactions were prepared in a final volume of 25~1. Each reaction 
contained 0. 75JJI of 50mM MgCb, 2. 5~1 of 10 x NH4 buffer, 0.1JJI of Biotaq DNA 
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Polymerase, 0. 5~1 of 100mM deoxynucleoside triphosphate stock, 0.5~1 of 
reverse and forward primer (50pmol cone}, 1 ~I of eDNA sample and was made up 
to 25~1 with distilled water in PCR tubes. Samples were then placed in a PCR 
thermocycler. 
Primer design and RT- PCR conditions 
Primer design and optimisation conditions are described in detail in Chapter 7. All 
of the PCR reactions were prepared to a final volume of 25ul as described 
previously. For each primer pair the PCR conditions were optimised using 
positive controls. Following optimisation, isoform specific RT- PCR reactions 
were carried out using 1 ul of eDNA from1 0 different matched normal and tumour 
colorectal samples. 
PCR running conditions were as follows; 94°C for 2mins, 35 cycles of 94°C for 20 
sec, 56°C for 30 sec, 72°C for 40sec followed by a final elongation step of 72°C 
for Smin. The primer sequences and annealing temperatures and are shown in 
Table 2.2a. All of the PCR products were resolved on agarose gel as described 
previously. The gel concentration varied between 2-3%, depending on the size 
of the fragments that needed to be resolved. Sui of the PCR product was run 
alongside O.Sug of 1 00 bp DNA ladder on an agarose gel. 
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2.17 Sequencing of Beta 1 lsofonn 
For this purpose the QIAquick gel extraction protocol was used. The fragments of 
interest were excised from the agarose gel and weighed. The samples were 
incubated in 3 volumes of buffer QG to 1 volume of the gel until the gel slices had 
dissolved. The samples were then placed in a QIAquick spin column and 
centrifuged to bind DNA. A series of washes were carried out where buffers were 
added to the QIAquick columns and centrifuged to remove all of the agarose and 
salts. The samples were eluted in 30ul of EB buffer. The samples were analysed 
on a gel following elution. 
Each fragment (top and bottom band) was taken through a PCR reaction using 
the Big Dye Cycle sequencing kit. Each reaction contained, 2ul of the terminator 
ready reaction mix, 6ul of dilution buffer (200mM Tris-HCL (pH 9), SmM MgCI2), 
Sui of DNA template and 1 ul of Spmole primer. The final volume was made up to 
20ul with distilled water. For each fragment the reaction was carried out with both 
the forward and reverse primer sequence. The PCR products of the sequencing 
reaction were purified (Big Dye Version 3) and sequenced at the Functional 
Genomics Unit (University of Birmingham). 
The sequencing data obtained for each fragment sequence was put through a 
Blast search (NCBI website) and the top band was found to contain the exon 1 0 
sequence which is specific to NRG1- Beta 1. 
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2.18 Real -time RT- PCR 
In comparison to reverse transcriptase - PCR, real-time PCR 
allows quantitation of eDNA /DNA and collects data whilst the reaction is 
proceeding. Real-time PCR products are detected via the generation of a 
fluorescent signal. Samples are analysed using an ABI Prism 7700 Sequence 
Detection System The machine contains a sensitive optical detection system that 
monitors the fluorescence in each well of a 96 well-plate reaction at frequent 
intervals during the PCR reaction. 
For the purpose of this analysis SYBR Green, a fluorogenic dye, was used for 
real-time analysis. SYBR Green binds the minor grooves of double stranded 
DNA causing fluorescent emission. As double stranded DNA is synthesized, 
more SYBR Green will bind and fluorescence is increased. 
2.18.1 Primer Design 
Quantitative real-time PCR primers were designed using the Primer Express 
version 1.5 programme (Applied Biosystems). Whilst designing primers the 
following guidelines were used: G-C content was kept in the 30-80% range, runs 
of an identical nucleotide were avoided (especially true for guanine, where runs of 
four our more Gs should be avoided), the Tm was kept between 58-60°C, no 
more than two G and/or C bases were present in the five nucleotides at the 3' end 
and finally the maximum amplicon size did not exceed >150 basepairs. The 
primer sequences are shown in Table 2.3. 
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2.18.2 Quantitation of primers 
All primers were quantitated using spedophotometry to determine the 
concentration of the primers. The absorbance was measured at 260nm and the 
extinction coefficient contribution was calculated for each primer using the values 
in Table 2.5. 
Extinction Extinction ~hromophore Coefficient Number Coefficient Contribution 
A 15,200 1 15,200 
c 7,050 6 42,300 
G 12,010 5 60,050 
T 8,400 6 50,400 
Total 167,950 
Table 2.5: Extinction coefficient contribution 
Finally the oligonucleotide concentration (C) in uM was calculated using the 
equation below: 
Absorbance (260nm) =sum of extinction coefficient contributionsx cuvette 
pathlength x oligoneucleotide concentration /100. 
The primers were made up to a 51Jmole concentration and primer dilutions of 
50/50(0.751JI), 300/300(91-'1) and 900/900(13.5!-'1) were used for optimisation on 
positive controls. 
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2.18.3 Preparation of Real-time RT-PCR samples 
All PCR reactions were prepared to a final volume of 25J,JI using reagents 
described previously. Each PCR reaction contained 1J,JI of eDNA, 12.5J,JI of 2x 
master-mix (Applied Biosystems) F' and R' primer (volumes used are shown in 
Table 2.6 below) and each reaction was made to a final volume of 25J,JI with H20. 
Primers Concentration Volume ofF' Volume ofR' primer(ml) primer (ml) 
Beta -1 300/300 1.5 1.5 
NDF-43 900/900 4.5 4.5 
Beta -3 300/300 1.5 1.5 
Gamma 900/900 4.5 4.5 
KRT-8 300/300 1.5 1.5 
Table 2.6: Primer concentrations of NRG1 isoforms used for real-time PCR 
analysis 
The Beta isoforms as previously mentioned are expressed in breast and 
pancreatic tissues. The pancreatic cell line BxPC3 and MDA- MB231 , breast 
carcinoma cell line were used as positive controls. HEK- 293 (human embryonic 
kidney cell line) was used as a positive control for HRG1 - Gamma. eDNA was 
synthesised from in- house RNA extractions of HEK-293, MDA-MB231 and 
BxPC3 cell lines. eDNA synthesis was carried out using previously described 
method . Stromal and inflammatory contents may vary between normal and 
tumour samples therefore the epithelial cell specific gene cytokeratin 8 (KRT 8) 
was used as an internal control. 
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Negative controls for each real-time PCR reaction included distilled H20 and 
Dnase treated RNA was included for PCR reactions where the primers were not 
designed across intron/exon boundaries. All reactions were carried out in 
triplicate on a 96 well reaction plate (ABI). Triplicate positive and negative control 
were included for each primer reaction. 
2.18.4 PCR conditions 
PCR conditions were as follows; 95°C for 10m ins, followed by 40 cycles of 95°C 
for 50 sec and oooc for 1 mins. The PCR reactions were performed using ABI 
Prism 7700 sequence detector (Applied Biosystems). 
2.18.5 Optimisation of real-time RT -PCR primers 
The real-time PCR products were run on a agarose gel stained in SYBR green 
dye solution (Applied Biosystems) to check that there were no primer dimers and 
the Ct values were genuine 
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Results 
Chapter 3 
Identification of bacterial artificial chromosome 
clones (BACs) containing the NRG1 gene and 
deletion analysis of NRG1 in colorectal tumours 
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3.1 Introduction 
Previous LOH studies identified a distinct region of interstitial deletion at the 
c8p12 locus in early colorectal tumours. Fine mapping of the c8p12 deletion 
region demonstrated the deletion region lay between markers D8S87 
(centromeric) and WRN gene (telomeric). The wide range of context dependant 
functions of the NRG1 ligands and reported role in solid tumourigenesis 
suggested NRG1 was a good candidate gene to study in colorectal 
tumourigenesis. 
From the previous study it was not clear where the telomeric breakpoint lay 
relative to the candidate gene (NRG1). In the colorectal tumour samples 
examined, markers D8S535, 08S259 and E8.1 C were deleted and the WRN 
gene was retained (as shown in Chapter 1, Figure 1.1). The NRG1 gene lies 
telomeric to marker D8S259 which was deleted in 70% of T1 rr2 tumours and 
was retained in node positive cancers (Table 1.1 ). In order to establish whether 
this site of interstitial deletion encompassed the NRG1 gene, early (T1fT2NOMO) 
tumour samples with 8p12 deletion were analysed by comparative genomic 
hybridisation (CGH) and fluorescent in-situ hybridization (FISH). 
Fluorescent in-situ hybridisation (FISH) 
FISH has proven to be an important tool in the cytogenetic analysis of tumours. 
As well as allowing the identification of specific chromosome abnormalites, it 
allows the characterization of commonly deleted regions and the identification of 
translocation breakpoints. FISH is based on the hybridisation of single stranded 
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DNA molecules (probe) to target complementary sequence. The detection of 
fluorescent target in turn allows the number, size and location of specific DNA 
sequences to be determined microscopically (Tkachuck et al 1991 ; Reid et al 
1999). 
Probes used for FISH applications bind to regions of cytogenetic interest and are 
classified in to three main categories, each with a different range of applications: 
Repetitive -sequence probes target chromosomal regions that contain short 
sequences present in abundance such as alpha satellite probes which target 
alpha satellite DNA present in the centromere. 
Whole chromosome probes have sequence homology at many sites along one 
chromosome type and enable staining of the entire chromosome. 
Locus specific probes target specific sequences ranging from 15 - 500kb on a 
chromosome and allow study of loci important in genetic disease. 
For the purpose of this study, an alpha satellite chromosome 8 centromeric 
probe was used as an internal control/reference to confirm chromosome 
localisation of the NRG1 probe. Probes used for FISH analysis are cloned in a 
variety of vectors such as plasmids, PAC, BAC and yeast artificial chromosome 
clones (YAC) (Tkachuck et al 1991; lourov et al 2005). In this study BAC clones 
were selected for FISH analysis. BAC vectors can accommodate DNA inserts up 
to 300kb. BAC DNA exists in supercoiled circular form that permits easy isolation 
and manipulation with minimal breakage. The other advantages of BAC clones 
include clonal stability and low rate of chimerism (Shizuyu et al., 1992; Gong et 
al. , 2002, Marra et al. , 1997; Strachan & Read.,1999) 
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This chapter describes the approaches used to identify bacterial artificial 
chromosome clones (BACs) containing the coding sequence of the candidate 
gene NRG1 and the approaches used to verify the sequence and chromosomal 
location of the BAC clones. Finally, the findings of comparative genomic 
hybridisation (CGH) and fluorescent in-situ hybridisation analysis used to 
investigate NRG1 deletion in early colorectal tumours are discussed. 
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3.2 Results 
3.2.1 Identification of bacterial artificial chromosome clones (BACs) 
In order to identify BAC clones corresponding to the NRG1 gene at the c8p12 
locus, a computer-based search was performed using the ensembl genomic 
database (www.ensembl.org). A series of clones was identified from the 
Ensemble database (Build 35) as shown in Table 3.1 below. 
JhsemljiD Synonym •tart end 
INSGOOOOOJ57168 NRGl 31617043 32741561 
Intnl clone Accession Build35 BWd35 end 
Name NlBllber start 
RP11-97N152 AC104000 31524467 31681321 
RPll-478814 AC104029 31596486 31773928 
RP 11-650811 AC068931 31728031 31829504 
RP11-147C21 AC022833 31816328 31993346 
RP11-22F19 AC021909 31907984 32086604 
RP11-275E10 AC022850 32082920 32253196 
RP11-669822 AC023948 32146563 32342543 
RP11-468C1 AC068359 32307542 32493998 
RP11-317J8 AC083977 32443776 32656330 
RP11-30IH15 ACOI3561 32530006 32715284 
CfD-2329M5 AC103675 32623526 32733075 
Table 3.1 Bacterial artificial chromosome clones across the NRG1 gene: 
This table represents the BAC clones across the entire genomic sequence of 
the NRG1 gene according to ensemble database (Build 35). 
(www.ensembl.org) 
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A map was constructed of the location of available BACs relative to the NRG1 
gene as shown in Figure 3.1 . 
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RP11-97N12 
~ .... 
RP11-478B14 
~ .... 
RP11-650B11 ~ .... 
~ 
571606 
RP11 -275E10 
~ .... 
RP11-669B22 
~ .... RP1 1-2329M5 ~ .. 
RP11-468C1 
~ .. RP11 -317J8 
RP11-1002K11 
~ .... 
~ .... 
RP11-301 H15 
~ .... 
44073 ~ 
291665 9555 2269 79562 598 4786 2n5 2810 
Figure 3.1 Distribution of BAC clones relative to the intron/exon sequence of the NRG1 gene: This figure 
illustrates the distribution of the various BAC clones relative to the intron/exon sequence of the the NRG1 
gene. The green boxes represent exons of NRG1 gene and the black bars represent the introns with the size of 
each intron represented in blue. The double arrowed bars represent SACs spanning this region of the genome. 
BAC clones RP11-301 H15 and RP11-317 JB lie across exon 7, which represents the common EGF functional 
domain of the NRG 1 gene and is found in all of the alternatively spliced isoforms. 
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BAG clones RP11-301 H15 and RP11-317 J8 were selected for NRG1 deletion 
analysis. These BACs covered most of the exons of the NRG1 gene, and, 
importantly, cover exon 7 which encodes the functional EGF domain, found in all 
alternatively spliced isoforms of the NRG1 gene. 
3.2.2 DNA extraction, preparation and detection of fluorescent labelled 
probes: 
This has been previously described in Chapter 2. 
3.2.3 Verification of chromosome localisation of BAC clones by FISH 
To confirm chromosomal localisation of the clones to the c8p12 region, 
hybridisation of the fluorescent labelled DNA probes was carried out on normal 
lymphocyte metaphase spread. Metaphase spreads were used as they permit 
chromosomes to be differentiated by their size, position of centromere and 
banding pattern and permit localisation to a resolution of- 5-1 0 mbp. Slides 
were examined under a fluorescent microscope using Smart Capture software. 
Despite numerous attempts, the quality of DNA extracted from clone RP11-
317 J8 was too poor to allow further analysis of this clone. Clone RP11 -301 H15 
(purchased from RPCI) according to the Ensemble genomic database 
corresponded to the c8p121ocus however, it was found to hybridise to 
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chromosome 22 (confirmed by size and banding pattern) instead of chromosome 
8 as shown in Figure 3.2 below. This emphasised the importance of screening 
purchased clones to ensure that they localise to the region of interest. 
Green Be probe 
IQIJvii'IO"-' with 
antidig-FITC 
Red anti-avidin 
Cy3 probe labelled 
with FITC detected 
on chromosome 22 
Figure 3.2 FISH of clone RP11-301H15 to chromosome 22: Lymphocyte 
metaphase spread showing hybridisation of clone 301-H15 to chromosome 22 
therefore confirming that this clone does not correspond to the 8p12 region. 
In light of the above findings, subsequent BAC clones were screened by reverse 
transcriptase-PCR (RT -PCR) using STS microsatellite markers mapped to the 
c8p12 region, providing a quick way of screening clones before FISH analysis. 
3.2.4 Screening of bacterial artificial chromosome clones by RT -PCR: 
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Identification of microsatellite markers 
RT -PCR using STS microsatellite markers was used for initial screening of 
clones. BAC clones to the c8p1 2 1ocus (a kind gift from Dr P.Edwards, 
Cambridge) were used for further analysis. In order to determine whether these 
BAC clones contained coding sequence of the NRG1 gene the ensemble 
database was searched for microsatellite markers that had been mapped to this 
region which are shown in Table3.2 & Figure 3.3. 
Marker Location 
0852063 31703894 - 31703988 
0851810 31811263-31811447 
0852319 31935074 - 31935202 
AFMA143YG9 32098397-32098520 
0851477 32186709 - 32186878 
088499 32261497 - 32261631 
0851125 32487058 - 32487283 
085375 32577362 - 32577489 
085278 32667932 - 32668167 
•u-s47Ql 
I I I 
oes2or.3 oss1e1o o8S2319 
31.i t Kb 31.8t Kb 32 ••• Kb 32.20 Kb 
Table 3.2 showing list of 
markers spanning the NRG1 
locus. 
I I I 
oes; u 2s oss278 
08!;37S 
11111
NRG1 
32.4. ltb 32.60 ltb 32.80 ltb 33 
-------------2 .•• Kb -------- -------
Figure 3.3 Microsatellite markers mapped to NRG1 gene at the c8p12 
locus: Map of the c8p12 region showing the position of microsatellite markers 
(shown in pink) relative to clones across the NRG1 gene (www.ensembl.org). 
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Screening of BAC clone RP11-301 H15 by PCR using microsatellite marker 
085375 
BAG clone RP11-301 H15 (gifted by Dr P.Edwards), which covers most of the 
exons of the NRG1 gene and more importantly covers exon 7 (which contains 
the functional EGF domain) was screened by RT-PCR using STS microsatellite 
marker 085375, which had been mapped to this region as shown in Figure 3.4. 
- - ---------- -----------
p12 
I** .... I*'* ..... ,. .... f* --, f* ... 
32,Se ltb 32.6t ltb 32.7e ltb 32.8 t ltb 32.90 lib 33. 01 ltb 33. 10 lib 33.2t lib 3S.3t ltb 33.U ltb 
- ---· --- -lHl<cootigs) 
11arkers 
·~ .· ~OG83S9 > H~'~ AC!'.l020+ At10~037 > 
• 
D8Sli77 08S499 08!;1125 08S37S 08S278 D8S7 1 
Ens~l Genes 
LMRG1 
Gene legend - ENSEHBL PREOIC'T!O GENES <KNO~tl> - EIISEIIBL PREDICTfO GEllES <NOIJEU - ENSEHBL PSEUOOCENES 
Figure 3.4: Chromosomal location of marker 085375 
Micosatellite Marker Locus Primer Sequence 5'- 3' 
D8S375 8p12 TTA CAC TAT CTG AAG GAG TGT 
ACA CAT ATA GGG AAG AAC TCT 
Table 3.3 shows the primer sequence used for RT -PCR screening of BAG 
clones. 
(www.ensemble.org) 
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RT-PCR was carried out on a series of BAC clones with microsatellite marker 
088375. Genomic DNA was used as a positive control and clones RP11-22F19, 
RP11 -97N12, RP11 -275E10, Rp11-478814, RP11-650811 , RP11-669 822 and 
Hi> was used as a negative control. Clone 301-H 15 was positive for marker 
088375 as shown in Figure 3.5a. Although a PCR product was seen for BAC 
clone RP11-275E10, this was of an incorrect size and could be due to the 8T8 
marker primers annealing to similar sequences found in this done. DNA 
extracted from BAC clone 301 -H15 was also positive for marker 088375 as 
shown in Figure 3.5b. 
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DNA 
301 H15 Genomic H20 
Clone DNA 
Figure 3.5 a &b: RT -PCR screening of BAC clones using marker 088375. Figure 3.5a: RT -PC R screening of 
BAC clones identified a positive clone RP11-301 H15 for marker 085375 Figure 3.5 b: RT -PCR using marker 085375 
showing a 124 base pair product for clone RP11 -301 H15 and from DNA extracted from this clone 
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3.2.5 Localisation of BAC clone RP11-301H15 by fluorescent in-situ 
hybridisation 
Mapping of RP11- 301 H15 BAC clone to chromosome 8 by FISH 
To confirm the chromosomal localisation of clone RP11-301 H15, fluorescent in-
situ hybridisation was performed on metaphase spreads of lymphocytes, 
obtained from normal individuals. The position of hybridisation of the fluorescent 
labelled RP11-301 H 15 DNA probe, was assessed relative to chromosome 8 
centromere specific probe. This confirmed localisation of clone 301-H15 to the 
short arm of chomosome 8 as shown in Figure 3.6 and this clone was used 
subsequently for NRG1 deletion analysis. 
Red anti-
avidin Cy3 
probe 
Green Be 
probe labelled 
with antidig-
FITC 
Figure 3.6 Lymphocyte metaphase spread showing hybridisation of clone 
.301-H15 to chromosome arm 8p12: Normal lymphocyte metaphase spread 
showing hybridisation of the NRG1 probe (RP11-301 H 15 in red) to the short arm 
of chromosome 8. The NRG 1 probe signal is located towards the centromeric 
end of chromosome arm 8p. 
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3.2.6 Clinicopathological and 8p12 deletion status of tumour samples used 
for deletion analysis 
Colon tissue samples were obtained in accordance with local ethical procedures 
from patients who had undergone surgery for colorectal cancer. The tumour 
samples were frozen and stored in liquid nitrogen. 
All tumour samples were staged according to the TNM classification. All tumours 
were left sided tumours. Five early (T1ff2NOMO) colorectal tumour samples 
were selected for deletion analysis. All of the tumour samples used for this 
analysis had confirmed localised 8p12 deletion between marker 08887 and 
WRN gene by previous FISH analysis. All samples had deletion of maker 
085259 as shown in Table 3.4 below. 
Table 3.4: Deletion status of tumour samples used for FISH analysis 
Marker Marker 
Sample Stage.TNM 08887 08S259 
61 T1NOMO D D 
60 T1NOMO D D 
62 12NOMO N D 
63 T1NOMO N D 
64 T1NOMO N D 
Pathology: All samples analysed were left sided lesions (Rectal cancers 
except sample C rectosigmoid carcinoma) Key: D=Deletion, N=no deletion 
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3.2. 7 CGH array in NRG1 deletion analysis 
In order to determine whether NRG1 was included in the deletion region, an 
early tumour sample with established c8p12 deletion was analysed by CGH 
array. This work was done in collaboration with Dr P.Edwards, Cambridge. One 
of the reasons for choosing CGH array for NRG1 deletion analysis in previously 
characterised early tumours was that it would allow us to determine whether our 
previous 8p12 deletion findings were consistent with data obtained from CGH 
array. CGH allows the whole genome of the tumour to be analysed for the 
detection of other chromosomal abnormalities, more importantly identifying 
chromosomal abnormalities that predominate in early tumourigenesis. CGH 
array analysis was performed across the whole genome of tumour sample with a 
series of clones (BAC), with high resolution on chromosome 8. 
A series of BAC clones spanning a region of approximately 9.5MB between 
c8p12 and c8p11 .2 loci were used for CGH analysis as shown in Figure 3. 7 The 
plot of c8p12 is on a log 2 ratio scale and the zero line indicates 2 copies of the 
chromosome if the ploidy of the sample is normal. The sample showed loss of 
the 8p12 region from BAC RP11-473A17 (containing the WRN gene) up to BAC 
CITB-D2343B20 encompassing the NRG1 locus. BAC's RP11-301 H15 and 
RP11-317 J8 both contain coding regions from the gene were used as probes. 
Deletion of NRG1 was confirmed as both of these probes gave values below the 
zero line. 
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Figure 3.7: CGH array on an early colorectal tumour sample (60). 
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CGH analysis on an early (T1 NOMO) colorectal tumour sample previously examined for c8p12 deletion. The 
c8p12 plot is on a log2 ratio scale and the zero line indicates 2 copies of the chromosome ie normal ploidy. 
The pink dotted line represents the localised 8p12 deletion found in colo rectal tumours. BAC RP11-301 H15 
to the NRG1 gene, lie below the zero line, indicating loss of NRG 1 in this tumour sample. 
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Within the deletion region an increase in copy number) was seen for 2 BACs, 
RP11-79H13 (position 34.96MB) and RP11-87N16 (position 35.06MB. The array 
data of this tumour sample also showed gain of chromosome arm 8q. 
The genome plot of this tumour sample showed small regions of gain at the 
c8p12-c8p11 .2. Amplification was also seen of chromosome13, 20 and of the 8q 
ann of chromosome 8. 
The CGH findings prompted us to extend our analysis of deletion on a panel of 5 
early colorectal tumours with previously established 8p12 deletion shown in 
Table 3.4. 
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3.2.8 FISH on panel of 5 early T11T2 colorectal tumour samples 
Quantification of FISH signals: 
For each tumour sample, 100 tumour cell nuclei were identified and scored for 
both Cy3 (NRG1) and FITC (8 centromere) signal. The presence of deletion was 
defined as cells which had fewer Cy3 signals than 8p centromeric FITC signals 
as shown in Figure 3.8 below. Cells that appeared intact and were not 
overlapping were counted. In order to limit false positives, cells with no 8 
centromere (FITC) signal were discarded for deletion scoring. 
8C probe 
labelled with 
antidig-FITC 
Red anti- avidin 
Cy3 labelled 
HRG1 probe. 
Figure 3.8 NRG1 deletion analysis- Fluorescent In-situ Hybridisation (FISH) 
on an early colorectal tumour sample: Colorectal tumour cell nuclei with only 
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one copy of NRG1 signal (Cy31abelled probe). Some tumour cell nuclei showed 
homozygous loss for NRG1. 
3.2.9 Analysis of NRG1 deletion in early and advanced colorectal tumours 
The percentage of cells with loss of NRG1 (< 2 copies of NRG1 signal/cell) was 
>50% (range 63-96%) in 4/5 tumour samples (samples B-E) examined as shown 
in Table 3.5 below . The percentage loss of NRG1 per chromosome was 
defined as: 
(Total no of 8C signals- Total no of signals) 
X100 
Total no of 8C signals 
Samples Stage %loss No of chromosome SC I No of NRG1 signal/ cell 
of cell 
NRG1 1 2 3 4 0 1 2 3 4 
by cell 
A (61) T1NOMO 38 I 45 35 19 5 33 44 14 4 
8 (60) T1NOMO 63 0 43 16 41 2I 42 34 3 0 
c (62) T2NOMO 94 0 99 I 0 38 56 6 0 0 
D (63) T1NOMO 98 I 95 4 0 77 21 1 1 0 
E (64) T1NOMO 96 1 99 0 0 65 31 3 1 0 
Table 3.5: NRG1 deletion analysis by FISH on early colorectal tumour samples 
BAC RP11-301 H15 to the NRG1 gene and 8 centromere probe were used for this 
analysis. The NRG1 gene copy and 8 centromere copy no was determined in 100 
tumour cell nuclei for each sample analysed. The% loss of NRG1 per cell was >50% 
in 4/5 tumour samples. 
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Analysis of the ploidy status of these tumour samples revealed 2 groups, 
aneuploid tumours (samples A &B) and euploid tumours (samples C-E). 
Tumours were defined as being aneusomic if the number of centromeric signals 
was different from the 2 signals corresponding to disomy in 20% of the tumour 
cell nuclei . This threshold value was in keeping with previous published reports 
(Di Vinci A, Cytometry 1999). Aneusomy of chromosome 8 was detected in 
samples A and B. In sample A, trisomy of chromosome 8 was detected in 35% 
of tumour cell nuclei, tetrasomy in 19% of tumour cell nuclei and monosomy of 
chromosome 8 was found in 1% of tumour cell nuclei. In sample B, 41% of 
tumour cell nuclei were tetrasomic for chromosome 8 and 16% of cells had 
trisomy of chromosome 8 as shown in Figure 3.9 below. 
Tumour A TumourB 
Figure 3.9: Tumour cell nuclei with aneusomy of chromosome 8 centromere. 
Sample A: Tumour cell nuclei with tetrasomy of chromosome 8 centromere and 
single copy of NRG1. Sample B:Tumour cell nuclei showing tetrasomy of 
chromosome 8 centromere and loss of NRG1 
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Homozygous loss of NRG1 was detected in the euploid tumour group compared 
to aneuploid group. Comparison of NRG1 copy number between aneuploid and 
euploid tumours i.e. A&B v C,D&E revealed no significant difference in the 
number of cells with copy number greater than 2 between the two groups (t-test, 
equal variances not assumed, p=0.17). The NRG1 copy number was found to 
vary directly with 8 centromere signal, such that the number of cells with more 
than 2 copies of 8C correlated with number of cells with more than 2 copies of 
NRG1 . This was statistically significant (Pearsons correlation coefficient, p=0.02, 
r=0.93). No significant pathological difference was identified between the 2 
tumour groups. All of the tumours analysed were left sided lesions with no lymph 
node involvement. 
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3.3 Discussion 
CGH array analysis of one tumour sample (Sample 60) showed small regions of 
gain at the c8p12-c8p11 .2. Within the deletion region an increase was seen in 
copy number of 2 BACs, RP11-79H13 (position 34.96MB) and RP11-87N16 
(position 35.06MB). In addition amplification of part of the genome containing the 
FGFR1 gene (fibroblast growth factor receptor 1 gene) was noted. In response 
to ligand binding to this receptor a cascade of down stream signals are triggered 
which influence mitogenesis and differentiation. Amplification of this receptor 
has been previously documented and expression of this receptor has been 
reported in colorectal cancer (Adelaide et al., 2003; Courtay-Cahen et al. , 2000; 
Nakao et al., 2004). An increase in copy number of these fragments of DNA may 
indicate translocation events at this locus. Translocations involving the 8p region 
have been reported in solid tumours and in haemopathies (Birnbaum et al. , 
2003). 
The array data of this tumour sample also showed gain of chromosome arm 8q, 
amplification of chromosome13, 20 and loss of 4p and chromosome 18. Similar 
findings have been reported in colorectal tumours. The putative conditional 
tumour suppressor gene Deleted in colorectal cancer (DCC) is located on 
chromosome arm 18q and has been associated with the progression of 
colorectal cancer (Rodrigues et al., 2007). The MMP-9 gene (matrix 
matalloproteinases-9 gene) is located on chromosome arm 20q, and increased 
levels of MMP-9 have been shown to be associated with metastatic colorectal 
cancer (Nakao et al. , 2001 ; AI-Mulla et al., 1999). Overall CGH analysis revealed 
loss of the c8p12 locus in early colorectal tumourigenesis. 
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Despite numerous attempts and adjustments in extraction methods, DNA 
isolation from clone RP11-317-J8 was not successful. Also screening of BAC 
clone RP11-301 H15 (purchased from RPCI) with FISH revealed hybridisation to 
chromosome 22. The use of FISH as a first option to verify clones proved to be 
time consuming as well as technically demanding. In view of this RT-PCR using 
microsatellite markers was used to provide a quick and easy way of identifying 
positive clones. BAC clone RP-301 H15 (purchased from RPCI) was found to 
hybridise to chromosome 22, however clone RP11-301H15 (Cambridge) 
hybridised to the c8p12 region. The most likely explanation for this finding is that 
an incorrectly labelled clone had been purchased. 
As shown in Table 3.5, the proportion/number of cells with loss of NRG1 (< 2 
copies of NRG1 signal/cell) was >50% in 4/5 (80%) of tumour samples. An 
interesting finding in tumour samples A and 8 was the presence of subclones of 
cells with trisomy and tetrasomic chromosome 8. Loss of symmetry in 
chromosome division is likely to generate subclones with an abnormal number of 
chromosomes in tumour samples. In addition, chromosome instability within 
these subclones will allow the existence of different subclones within the same 
tumour (DiVinci et al. , 1999). 
Increased range of DNA copy number alterations of both the 8 centromere and 
the NRG1 gene was observed in the aneuploid group of tumours. Chromosomal 
gains and losses are recognised to be a common finding in aneuploid tumours 
(Giaretti et al. , 1994; Reid et al., 1999; Sugai et al. , 2000) The NRG1 copy 
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number varied directly with 8 centromere signal (statistically significant Pearsons 
correlation coefficient, p=0.02, r=0.93). 
Although the number of early tumour samples analysed were small, overall 
NRG1 was consistently deleted and FISH analysis confirmed that NRG1 was 
within the localised c8p12 deletion region. Tumour samples used for NRG1 
deletion analysis had been previously characterised for 8p12 deletions. In order 
to verify that the 8p12 deletions were consistent, advanced colorectal tumours 
with established 8p12 deletion were examined and NRG1 deletion was also 
identified in these tumours. 
We next went on to investigate whether the protein products of the NRG1 gene 
were expressed in normal colonic mucosa and in tumours with established 
NRG1 deletion. 
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RESULTS 
CHAPTER4 
Expression of NRG-1 protein (heregulin) and 
erbB2 protein overexpression in colorectal 
tumours 
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4.1 Introduction 
Following FISH analysis, expression of NRG1 proteins was investigated by 
immunohistochemical analysis in matched normal/ tumour colorectal samples. 
Having confirmed deletion of NRG1 in early tumours, we investigated whether 
deletion of one allele of NRG1 influences protein expression. The NRG1 proteins 
are alternative spliced products of a single gene that differ in their N-termina, the 
presence or absence of a transmembrane domain, the type of EGF like domain 
i.e. a or ~ and the C-terminus (Falls, 2003, Lemke, 1996). Matched 
normal/colorectal tumour samples were stained with an antibody which detects 
the a and ~ isoforms of heregulin, a protein product of NRG1 . At the time of this 
study antibodies to other isoforms of NRG1 were not available. 
The NRG1 proteins, act as ligands for the erbB receptors and bind erb83 or 
erb84, indirectly inducing phosphorylation of erb82 through the formation of 
erb83: erb82 or erbB4: erbB2 hetrodimers serving as mediators of signal 
transduction (Venkateswarlu et al., 2002; Carraway et al., 1994; Varden et al., 
1991 ; Olayioye et al. , 2000). Overexpression of erb83 has been reported in early 
stage colorectal tumours with a reduction in prevalence being documented in 
advance stage cancers. Co-expression of erb83 and erb82 has also been 
reported to be significantly higher in early stage tumours. It is thought that erbB2 
:erb84 heterodimerisation may play a role in late stages of colorectal 
carcinogenesis (Lee et at., 2002). Activation of the MAPK pathway through 
overexpression of EGF co-receptor ErbB2 (a membrane receptor tyrosine kinase 
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factor in breast cancer (Lupu et al. , 1995; Olayioye et al. , 2000) In colon cancer 
cells, activation of the MAPK pathway through erbB2 has been reported 
(Venkateswarlu et al. , 2002). Establishing overexpression by 
immunohistochemistry is however, problematic, and this can be over- estimated 
(Nathanson et al., 2003). Given the different assay systems, antibodies and 
scoring systems in use, the FDA standardised HercepTest (Jacobs et al. , 1999; 
Perez, 1999) was used to analyse this tumour series for overexpression of erb82 
protein. 
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4.2 Results 
4.2.1 Clinicopathological and 8p12 deletion status of tumours used for 
immunohistochemical analysis of heregulin expression 
Paraffin sections of colorectal adenoma and tumour samples, along with matched 
normal tissue sections, were obtained in accordance with local ethical procedures 
from the Histopathology Department (Birmingham University Trust). Tumour 
samples previously used for NRG1 deletion analysis (highlighted in blue) were 
included in this analysis as shown in Table 4.1 below. 
Table 4.1 Histopathological grading of colorectal samples 
Advanced Early 
Early tumour tumour 
Advanced tumours samples samples 
tumour with without without Adenomas 
samples with 8p12 8p12 8p12 without 8p12 Adenomas with 
8p12 deletion deletion deletion deletion deletion 8_~?_12 deletion 
TV, moderate 
T3NOMO T1NOMO T3NOM1 T2NOMO dysplasia TV, severe dysplasia 
TV, moderate 
T4NOMO T1NOMO T3N2M1 T2NOMO dysplasia TV, severe dysplasia 
TV, moderate 
T4N1MO T2NOMO T3NOMO T2NOMO d_ys_21asia adenoma 
TV, moderate 
T4NOMO T1NOMO T3N1MO dysplasia adenoma 
TV, moderate 
T4N1MO T1NOMO qys_Qiasia 
(T3/T4NO node negative advanced tumours; T3/T4N1 node positive advanced 
tumours, T1/T2NO node negative early tumours; TV tubulovillous adenoma1 
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4.2.2 Optimisation of heregulin antibody 
Primary antibody 
A rabbit polyclonal antibody HRG (C-20) (Santa Cruz Biotechnology Inc), raised 
against a peptide at the carboxy terminus of the protein was used for this analysis. 
This antibody detects the a and 13 isoforms of heregulin and was selected as it had 
previously been tried and tested by different groups (Wang et al. , 2001 ; Aguilar et 
al., 2001 ; Shirakabe et al., 2001 ). 
Secondary antibody 
A biotinylated goat anti-mouse antibody (Dako, Carpentaria) was used for 
immunodetection. The avidin-biotin staining method was used to enhance 
detection of the target antigen by increasing the number of HRP molecules bound 
to the tissue. The product of reaction was identified using diaminobezidine (DAB). 
Controls 
Positive control 
The type I transmembrane neuregulins are expressed in breast, heart, liver, 
kidney, skeletal muscle, prostate, ovary and small intestine (UniProtKB/Swiss-
Prot, Le et al. , 2002). For the purpose of this study MCF-7 (breast carcinoma cell 
line) cells were selected for antibody optimisation. 
Heregulin Blocking peptide 
To test for antibody specificity, heregulin blocking peptide (100ug peptide in O.Sml 
PBS containing 0.1% sodium azide and 1 OOug BSA) was used as a negative 
control. 
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The primary and secondary antibody concentrations were titrated until good 
staining with little or no background was achieved. Following antibody 
optimisation, the working concentration of antibodies was applied to a panel of 
normal colon tissue paraffin sections as illustrated in Figure 4.1 . 
Primary ( 1 :200) and 
secondary (1 :500) 
antibody 
Secondary antibody 
only (1 :500 dilution) 
Figure 4.1 : Optimisation of HRG (C-20) antibody 
MCF-7 cells were used as a 
positive control (1 :200 primary 
antibody dilution and 1 :500 
secondary antibody dilution) 
Heregulin blocking peptide 
Top panel: shows optimisation of HRG (C20) antibody on MCF-7 cells. Good staining with 
minimum background was achieved with primary and secondary antibody concentration of 
(1 :200) and (1 :500) respectively. The blocking peptide was used on MCF-7 cells (figure not 
shown) and on paraffin sections. Bottom panel: Expression of heregulin in normal colonic 
mucosa. 
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4.2.3 Heregulin protein expression and stage 
Heregulin staining was detected in all matched normal samples and this staining 
pattern was used as an internal control for assessment of tumours. Most normal 
samples [13/17 (76%)], expressed weakly (1+) but this was seen in only a minority 
[2/17 (11 .7%)] of cancers, the remainder showing higher expression levels. 
Differences were also apparent between early and advanced tumours. Staining 
was strong (3+) in 4/9 (44%) advanced tumours compared to 3/17 (17.6%) 
adenomas and early tumours as shown in Table 4.2 and Figure 4.2 indicating an 
increase expression with tumour progression. 
lntensi ':'1 score 
Samples 0 1+ 2+ 3+ 
Nonnal 
N=17 0 13 4 0 
Adenomas 
N=9 0 3 5 1 
Early 
Tumours 
N=8 1 1 4 2 
Advanced 
tumours 
N=9 0 0 5 4 
Table 4.2: Heregulin protein expression in adenomas, early and advanced 
colorectal tumours. This table shows intensity of heregulin immunostaining in 
normal colonic mucosa, adenomas, early and advanced tumours. An increase in 
protein expression was noted with progression from normal mucosa to advanced 
tumours. 
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Normal colon mucosa 
(1 +, 1 0-25%) 
Blocking peptide on 
normal mucosa 
Adenoma (2+, 1 0-25%) 
Blocking peptide on adenoma 
Early tumour (2+, >75%) 
Blocking peptide on 
early tumour 
Advanced tumour (3+.>75%) 
Blocking peptide on 
advanced tumour 
Figure 4.2: Heregulin immunostaining in normal mucosa, adenoma, early and advanced colorectal tumour samples. In 
the top panel, heregulin expression is seen with progression from normal colonic mucosa to advanced tumours. Increased staining 
is seen in advanced tumours. The figures in brackets include intensity and proportion of tumour stained. The above tumour 
samples were negative for 8p12 deletions. Control samples are shown in the bottom panel. 
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The frequency of intensity score of 3+ was compared between normal, 
adenomas, early and advanced tumour groups using the Fishers exact test. 
The score was clearly more frequent in more advanced tumours in the table, 
and this was significant (p=0.01 ). Advanced tumours on average expressed 
more heregulin. The mean score per group was compared using the Kruskai-
Wallis test. After excluding samples with intensity score zero there was a 
statistically significant difference (p<0.0001 ). The mean score in each group, 
with the standard error of the mean in brackets, was as follows 
Normal = 1.24 (0.11 ), Adenoma = 1. 78 (0.22), Early = 2.14 (0.26), 
Advanced= 2.44 (0.18). 
In normal mucosa, heregulin was expressed predominately in the luminal 
epithelial cells whereas in tumour samples a diffuse staining pattern was seen 
in both luminal and epithelial cells and cells located deep in the crypts, as 
shown in Figure 4.3. 
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Figure 4.3: lmmunolocalisation of heregulin protein in matched normal 
colonic mucosa and advanced colorectal tumour. In normal colonic 
mucosa (A) heregulin was seen predominately in the cytoplasm of luminal 
epithelial cells. Minimum staining was noted in the cells located deep in the 
crypts. In matched tumour sample (B) a more diffuse staining pattern was 
noted. 
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4.2.4 Deletion status and heregulin expression 
Some variation in protein expression between early and advanced tumours 
according to the deletion status (loss of one allele of NRG1 ) was seen as 
shown in Table 4.3. However, this was not statistically significant. 
Samples 8p12 Intensity score 
Deletion 
status 0 1+ 2+ 3+ 
Normal No Deletion 0 13 4 0 
Adenomas Deletion 0 2 1 1 
N=4 
Adenomas No Deletion 0 1 4 0 
N=S 
Early Deletion 1 1 2 1 
tumours 
(T1ff?) N=S 
Early No Deletion 0 0 2 1 
tumours 
(T1ff2) N=3 
Advanced Deletion 0 0 2 3 
tumours 
(T3ff4) N=S 
Advanced No Deletion 0 0 3 1 
tumours 
(T3ff4) N=4 
Table 4.3: Heregulin expression in adenomas, early and advanced 
colorectal tumours with and without deletion. 
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In the advanced tumour group, comparing the frequency of score 3+ between 
deletion/no deletion tumours was not significant. (p=0.25, Fishers exact). 
If the mean intensity score was compared between the same groups (using 
the Mann-Whitney test) it was higher in those with deletion (2.60 v 2.20) but 
remained non significant (p=0.52). In adenomas and early tumours, a 
frequency of score 1 + or less was no different between those with and without 
deletion (p=0.20, Fishers exact). The mean intensity score was higher in 
those with no deletion (2.00 v 1.67) but this was not significant (p=0.48) 
4.2.5 ErbB2 protein overexpression 
The FDA approved Hercep Test and scoring system was used to investigate 
overexpression of erbB 2 protein (refer to Chapter 2 Methods and 
Materials). The Hercep Test was applied to the same cohort of tumour 
samples shown in Table 4.1 . This work was carried out in collaboration with 
Dr.P.Taniere (Consultant Pathologist, University Hospital, Birmingham). 
The Hercep- Test revealed over -expression of erbB2 protein in 3/9 advanced 
tumours and in only 2/17 adenomas and early tumours as shown in Table 4.4. 
The intense membranous staining seen in advance tumours was not restricted 
to the basolateral membrane were erb82 receptors are normally situated 
(Vemeer et al. , 2003) as shown in Figure 4.4. 
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Samples Erb82 OVER- EXPRESSION 
0 1+ 2+ 3+ 
Normal 17 0 0 0 
N=17 
Adenoma 8 0 1 0 
N=9 
Early 7 0 1 0 
tumour 
N=8 
Advanced 5 1 2 1 
tumour 
N=9 
Table 4.4: ErbB2 protein overexpression. Using the Hercep Test guidelines 
over-expression of erb82 was detected in 3/9 advanced tumour (score~ 2+) 
and in only 2/17 adenoma and early tumours. 
Figure 4.4: lmmunostaining of normal colonic mucosa (A), early (B) and 
advanced (C) colorectal tumours with Hercep Test. Over-expression of erb82 
protein was not detected in normal mucosa and in the early tumour sample. Over-
expression was detected in the advanced tumour as shown by the intense brown 
membranous staining seen in the tumour epithelial cells. 
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Statistical analysis of erb82 protein overexpression, comparing the frequency 
of score of <2 and greater than or equal to 2 was statistically non-significant . 
(p=0.30, Fishers exact). 
4.3 Discussion 
Immunohistochemical analysis of NRG1 isoform heregulin, overall identified 
increased expression in advanced tumours compared to normal mucosa, 
adenomas and early tumours. This was statistically significant (p=0.01 ). 
Comparison of heregulin expression between tumour groups with and without 
deletion using a number of statistical tests revealed no significant difference 
This may be a result of the small number of tumour samples analysed. Lack of 
availability of tumour samples with previously characterised 8p12 deletions 
prevented further analysis of the influence of deletion on NRG1 protein 
expression. It is therefore not possible to comment whether deletion of one 
allele of NRG1 had any effect on protein expression. 
Although, we identified erbB2 protein overexpression in advanced colorectal 
tumours (3/9 advanced vs. 2/17 early tumour and adenomas), small sample 
numbers prevented any meaningful analysis. Therefore heregulin and erb82 
protein overexpression were investigated in a large cohort of colorectal 
tumours. 
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Results 
Chapter 5 
Multiple tissue array analysis of heregulin protein 
expression and erbB2 protein overexpression in 
colorectal tumours 
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5.1 Introduction 
Immunohistochemical analysis of heregulin protein (chapter 4) identified 
increased expression in advanced tumours compared to normal mucosa, 
adenomas and early tumours, which was statistically significant (p=0.01 ). 
Although erbB2 protein overexpression was seen in advanced colorectal tumours 
(3/9 advanced vs 2117 early tumour and adenomas), this was statistically non-
significant. 
To extend the above finding, a multiple tissue array (MTA) of 250 colorectal 
tumours was used for immunohistochemical analysis (antibody optimisation 
previously described in Chapter 4) to establish the prevalence of heregulin 
protein expression and erbB2 protein overexpression in colorectal tumours. 
Clinical and pathological data were collected in accordance with ethical 
guidelines. 
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5.2 RESULTS 
5.2.1 Multiple tissue array analysis of heregulin protein expression 
and erb82 protein overexpression in colorectal tumours 
A MT A of 250 colorectal tumours was analysed for heregulin and Erb82 
overexpression and results were obtained for 165 cases. 73% of tumours were 
left-sided lesions (descending colon, sigmoid, rectosigmoid and rectal tumours). 
Heregulin was expressed in 73%, 58%, 60% of Dukes A, 8 and C tumours 
respectively, while erb82 protein over-expression was seen in only 6% of Dukes 
stage A, 11 .3% of Dukes stage Band 7.7% of Dukes C tumours as shown in 
Table 5.1 . 
Multiole Tissue Arrav IMTAl 
Stage +I+ + 1- -I+ 
-1-
A 1 10 0 4 
B 7 34 1 29 
c 5 42 1 30 
D 0 0 0 1 
Total 13 86 2 64 
Total no 
of 
tumour 
samples 
per stage 
15 
71 
78 
1 
165 
•Key: 
• +/+ Heregulin &Her-2 positive 
• +/- Heregulin positive & Her-2 
negative 
• -I+ Heregulin negative & Her-: 
positive 
• -I- Heregulin & Her-2 negativE 
Table 5.1: Heregulin protein expression and erb82 overexpression in 
MTA of colorectal tumours. In total, 60% (99/165) of tumours expressed 
heregulin protein and overexpression of erb82 was identified in 9% (15/165) 
of all cases. 
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Heregulin protein expression and tumour stage 
Heregulin expressing (positive) tumours were compared with tumours negative 
for heregulin expression for each tumour stage. No statistical difference was 
identified (p=0.45, fishers exact). 
Erb82 protein overexpression and tumour stage 
Tumours with overexpression of erbB2 protein were compared with tumours 
negative for erbB2 overexpression for each tumour stage. Again, no statistical 
difference was identified (p=0.86, fishers exact). 
Heregulin and erb82 positive tumours - Is there a correlation? 
13% (13/99) of heregulin positive tumours overexpressed erb82 protein 
compared with 3% (2/66) of heregulin negative tumours. The frequency of erb82 
positive tumours was compared between heregulin positive vs. heregulin 
negative samples. This was found to be significant p=0.027, chi sq=4.889. 
A further group of tumours was identified 38.7% (64/165) which were negative for 
heregulin and erbB2 protein overexpression as shown in Table 5.1. 
5.2.2 Recurrence and tumour stage 
Of the 165 tumours investigated, recurrence (local/metastatic) was identified in 
22% (37/165) of patients. Recurrent disease was detected in 3% (1/37) Dukes A, 
35% (13/37) Dukes Band 62% (23/37) Dukes C patients. Although there was a 
trend towards greater recurrence with more advanced tumour stage (A=6.67%, 
8=18.31%, C=29.49%) this was not significant p=0.10 (chi sq). 
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Heregulin expression and Erb82 overexpression of primary colon tumours 
in patients with and with out recurrence 
Recurrent disease was detected in 37 of 165 patients with colorectal cancer. 
Heregulin expression and erb82 overexpression in the primary colon tumour 
samples of patients who developed recurrence are shown in Table 5.2 below. 
Stage +I+ + ,_ -I+ 
A 0 (1) 1 (9) 0 (0) 
B 0 (7) 7 (27) 0 (1) 
c 1 (4) 10 (32) 0 (1) 
D 0 (0) 0 (0) 0 (0) 
Total 1 (12) 18 (68) 0 (2) 
- 1-
0 (4) 
6 (23) 
12 (18) 
0 (0) 
18 (45) 
Total no 
of 
tumour 
samples 
per stage 
1 (14) 
13 (58) 
23 (55) 
0 (0) 
37 (127) 
•Key: 
• +/+ Heregulin &Her-2 positive 
• +/- Heregulin positive & Her-2 
negative 
• -I+ Heregulin negative & Her-2 
positive 
• -I- Heregulin & Her-2 negative 
Table 5.2: Heregulin and erb82 protein overexpression of primary colon 
tumours. Recurrent disease positive cases are shown in black and recurrent 
disease negative cases are shown in blue. 
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Heregulin protein expression and recurrence 
Comparing recurrence vs. no recurrence for heregulin positive tumours in all 
Dukes stages did not identify any significant correlation/relationship (p=0.30, Chi 
sq=1 .02). The same was true for heregulin positive tumours in each stage. 
ErbB2 protein overexpression and recurrence 
Comparing recurrence vs. no recurrence for erb82 positive tumours in all Dukes 
stages did not identify any significant correlation/relationship (p=0.19, fishers 
exact). 
5.2.3 Disease free survival (DFS) 
The hospital database and pathology records were used to calculate disease free 
survival (DFS). For each patient, date of operative procedure, date of recent 
clinic visit and date of diagnosis of recurrent disease if present was recorded. 
Follow up data was collected till June 2005 on patients who had undergone 
surgical resection between June 1997 and Feb 2002. 
Disease Free survival (DFS) and tumour stage 
The DFS data was obtained for 140 patients of which 12 were Dukes A, 61 were 
Dukes 8 and 67 Dukes C. The median disease free survival was 36.2 months. In 
the Dukes A group the median DFS was 63.1months (range 40-95 months). In 
the Dukes 8 and C groups the DFS was < 5 months in 15% (9/61) and 42% 
(28/67) of cases respectively. Comparison of the frequency of survival of< 
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Smonths between the Dukes Band C groups was statistically significant p=0.001 , 
Chi sq=11 .36. 
Heregulin and erbB2 status of tumours with DFS of < 5months 
The DFS for all stages and the heregulin and erbB2 status are shown in Table 
5.3 below. 
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Stage +I+ + 1- -I+ Total no 
_,_ 
of 
tumour 
samples 
per stage 
A 0 (0) 0 (9) 0 (0) 0 (3) 0 (12) 
B 1 (5) 3 (26) 0 (1) 5 (20) 9 (52) 
c 2 (2) 16 (19) 1 (0) 9 (18) 28 (39) 
D 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Total 3 (7) 19 (54) 1 (1) 14(41) 37 (103) 
Table 5.3 DFS ,heregulin and erb82 status in all tumour stages. The 
heregulin and erbB2 status of tumours with a DFS of < 5months are shown in 
black and tumour groups with a DFS of > 5months are shown in blue. In patients 
who had developed recurrent disease, DFS = Date of diagnosis of recurrence -
Date of operation. In patients who had no evidence of recurrence, DFS= Date of 
last clinic visit- Date of operation. 
The number of tumours (combining stages B &C, excluding stage A) that were 
heregulin positive was no different between those with a DFS of > 5 months and 
those with a DFS of < 5 months (p=O. 76 Fishers exact). When each stage was 
analysed separately, no significant difference was identified 
(Dukes stage B Fishers exact p=1 .00, Dukes stage C Fishers exact p= 0.39). 
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The above analysis was also carried out for erb82 protein overexpression and no 
statistical difference was identified between the number of tumours that were 
erb82 positive tumours between those with a DFS of less than 5 months and 
those with DFS greater than 5 months (Fishers exact p= 0. 7 4 ). 
This was also true when each stage was analysed separately (Dukes stage B 
Fishers exact p=1 .00, Dukes stage C Fishers exact p= 0.64). 
5.3 Discussion 
Previous immunohistochemistry analysis (Chapter 4) had identified increased 
expression of heregulin protein in advanced tumours (p=0.01 ) compared to 
normal mucosa, adenomas and early tumours. Similar findings have been 
reported in papillary thyroid cancer (Fiuge et al. , 2000). MTA analysis identified 
heregulin protein expression in 60% of tumours but no difference between 
number of heregulin positive tumours and stage (p=0.45) was identified. 
Overexpression of erb82 protein was identified in 9% (15/165) of tumours. A 
study by Nathanson et al. (2003) using the HercepTest reported a 3.6% (5/139) 
prevalence of erb82 overexpression, and Ramanathan et al. (2004) in reported 
overexpression of HER-2/neu in (8.0%, 11/138) of advanced colorectal cancer. 
Our findings were in keeping with the above studies. The prevalence of erb82 
overexpression in colon cancer ranges from 0-83% (Ross et al., 2001 , Caruso et 
al. , 1996) and this variation in data can be explained by technical variability, 
choice of primary antibody and differences in slide interpretaion. With the 
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exception of HerceptT est no standardised system exists to determine erb82 
protein overexpression by immunohistochemistry. 
Although overexpression of erb82 protein in colon cancer is low, erb82 has been 
reported to be widely expressed at nomal levels in colon cancer (Breuleux, 2007). 
The absence of erb82 expression in the remaining tumours cannot be confirmed 
as the HerceptTest assay detects only overexpression of erb82 protein. No 
statistical difference was noted between stage and erb82 protein overexpression. 
Similar findings have been reported by Kim et al. (2004) in tissue microarray of 
colorectal tumours. 
MT A analysis of tumour samples identified a significant correlation between 
heregulin expression and erb82 protein overexpression in tumours (p=0.027, chi 
sq=4.889). A further group of tumours were identified in which expression of 
heregulin and erb82 protein overexpression was not detected. 
A trend towards recurrence and advance tumour stage was noted. Liver 
metastasis (38%, 14/37) was the most frequent type of recurrence followed by 
local recurrence seen in 19%, (7/37) of cases. No statistical difference was 
identified with recurrence and heregulin expression and erb82 overexpression in 
all tumour stages. 
Disease free survival was worse in advanced tumour stage (DFS < 5 months 
Dukes 8 15% vs. Dukes C 42%) p=0.001. No association was identified between 
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disease free survival and heregulin expression for all Dukes stages. The 
association of erb82 overexpression with prognosis in colorectal is controversial 
with some studies reporting poor prognosis in erb82 overexpressing tumours. In 
our study, we did not identify any association between erb82 overexpression, 
tumour stage and disease free survival. Several studies have reported no 
prognostic significance of erb82 overexpression in colorectal tumours (Lee et al., 
2002; Osako et al. , 1998; Kim et al. , 2004; McKay et al. , 2002). 
In summary MTA analysis identified a significant correlation between heregulin 
expression and erb82 protein overexpression in colorectal tumours (p=0.027, chi 
sq=4.889). We further investigated heregulin expression by Western Blotting in a 
panel of normal mucosa, adenomas, early and advanced tumours, in samples 
previously used for immunohistochemical analysis. 
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RESULTS 
CHAPTER 6 
Western blot analysis of the NRG1 protein 
(heregulin) in colorectal tumours 
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6.1 Introduction 
Immunohistochemical analysis demonstrated significant (p=0.01) increased 
expression of heregulin protein in advanced colorectal tumours compared to early 
tumours and adenomas. The mean protein expression (intensity score) was higher in 
adenomas and early tumours with no deletion compared to adenoma and early 
tumours with deletion. The reverse finding was noted in advanced tumours, where 
the mean intensity score was higher in tumours with deletion. Although these 
immunocytochemistry findings were non-significant, semi-quantitative western 
blotting was used to further examine heregulin protein expression in these colorectal 
tumours. 
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6.2 Resutts 
6.2.1 Clinicopathological and 8p12 deletion status of colorectal tumour 
samples used for western blotting 
Samples used for Western Blot analysis are shown in (Table 6.1a). It was not 
possible to carry out western blot analyses on all of the samples used previously for 
immunocytochemistry, due to tumour tissue not being available. 
Sample No Histology Deletion status 
4 normal mucosa No deletion 
10 normal mucosa No deletion 
Tubulovillous adenoma, mild 
11 dys_plasia No deletion 
Tubulovillous adenoma, mod 
2 dysplasia No deletion 
Tubulovillous adenoma, 
7 severe dysplasia Deletion 
70 Early tumour T2NOMO No deletion 
64 Early tumour T1NOMO Deletion 
60 Early tumour T1NOMO Deletion 
6 Advanced tumour T3NOMO Deletion 
16 Advanced tumour T 4NOMO Deletion 
33 Advanced tumour T 4N 1 MO Deletion 
38 Advanced tumour T 4NOMO Deletion 
46 Advanced tumour T 4N 1 MO Deletion 
65 Advanced tumour T3NOM1 No deletion 
66 Advanced tumour T3N2M1 No deletion 
67 Advanced tumour T3NOMO No deletion 
Table 6.1a:Histopathological staging and deletion status of samples used for 
protein analysis (T1/T2 ear1y tumours, T3/T4 advanced tumours, NO node negative, 
N1 node positive, MOno distant metastases, M1 distant metastases) 
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Heregulin expression has been reported in human colorectal, ovarian, pancreatic, 
heart, liver, kidney and breast tissue (Le et al., 2002). In view of this cell lines shown 
in Table 6.1b were selected. 
Cell Une Tissue from which cell line derived. 
HT29 Colon Carcinoma 
HEK293 Human emb_ryonic kidney 
Colo320 Sigmoid colon Carcinoma 
Panc1 Pancreatic ductal Carcinoma 
BxPC3 Pancreatic Carcinoma 
HS578T Breast normal tissue 
HS174T Colon adenocarcinoma 
SW480 Colon adenocarcinoma 
Caco -2 Polarized cell line 
HCT116 Colorectal carcinoma 
MCF-7 Breast carcinoma 
Table 6.1b: Cell lines used for western Blot analysis . 
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6.2.2 Optimisation of heregulin antibody 
The heregulin primary antibody HRG (C-20) detects a and ~1 and ~2 isoforms of 
NRG1 protein. The molecular weight of NRG1-alpha isoform detected with this 
antibody is 44kDa. The molecular weight of NRG1 isoforms are shown in Table 6.2 
below. 
Amino Molecular 
NRG1 lsoforms acid weight 
length (Oa) 
NRG1-Gamma 211 22755 
N RG 1-Beta 1 645 71157 
N RG 1-Beta 2 637 70200 
N RG 1-Beta 3 241 26143 
NRG1- SMDF 296 31686 
NRG1- NDF 43 462 50748 
NRG1- GGF II 422 45141 
NRG1- Alpha 640 70392 
NRG1-Aipha 1a 648 71331 
NRG1 - Alpha 2b 4662 50879 
NRG1- Alpha 3 247 26590 
Table 6.2 Molecular weight of NRG1 
isoforms 
The HRG (C-20) antibody was optimised on a panel of breast, pancreatic and human 
embryonic kidney cell lysates shown in Figure 6.1 . Co-precipitation with the 
heregulin blocking peptide was used as negative control (as described in Chapter 2). 
A primary antibody concentration of 1 :500 and blocking peptide working 
concentration of 11JQ (5~1) of peptide, 1 IJI of primary antibody diluted in 1 ml of PBS 
was used. 
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160 
105 
75 
50 
44kDa ~ 
35 
30 
CaCo2 Pane 1 HT29 HCT116 SW480 BxPC3 LS147T 
52kDa 
Figure 6.1: Optimisation of HRG (C-20) antibody on cell lines. Although this 
antibody detects NRG1-alpha a 44kDa protein, molecular weight bands of 
160kDa, -90kDa, 70kDa and 30kDa were also detected. This antibody also 
detects NRG1-beta 1 & 2 isoforms, which are -71 and ?OkDa respectively and 
are seen in pancreatic cell lines (Pane 1 and BxPC3). The protein bands of 
160 and 90kDa could possibly represent non-specific antibody binding. To 
check for protein loading the membranes were reprobed with cytokeratin 8 
antibody. Equal protein loading was detected as shown by the cytokeratin 8 blot 
below. 
Optimisation of the primary antibody on cell lines showed protein bands of 160 
and 90 and 30 kDa band. It was not clear whether these bands were specific to 
primary antibody reaction. In light of this, heregulin blocking peptide was used as 
a negative control on cell lines and in tumour samples Figure 6.2a and 6.2b 
respectively. 
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HS578T Pane 1 HEK MW HS578T Pane 1 HEK 
293 293 
Figure 6.2a 
Blocking peptide Primary antibody. 
Cytokeratin 8 
Panc1 HEK293 60T 64T 61T 38T 46T Figure 6.2b 
190 
.. 
~ 86 I Blocking peptide 
70 
44 
22 
26 
17 
Panc1 HEK293 60T 64T 61T 38T 46T 
190 
86 I Primary antibody 
70 
- 44 
22 
26 
17 
Figure 6.2: Western Blot on cell lines and tumour samples using primary 
antibody concentration (1 :500) and heregulin blocking peptide (working cone: 
1 j.Jg (SIJI)of peptide, 1 IJI of primary antibody diluted in 1 ml of PBS). Bands of 
reduced intensity were seen with blocking peptide in both cell lines Fig 6.2a and 
tumour samples Fig 6.2b. The cytokeratin 8 antibody was used to check protein 
loading. (Fi<gure not shown for tumour samples) 
120 
As shown in Figure 6.2 a and b, bands between 85 kDa and 190kDa were 
noted with the HRG (C-20) antibody. lmmunoblotting with the heregulin 
blocking peptide, reduced the intensity of the bands seen using the HRG (C-
20) antibody on the cell lines and tumour samples examined however some 
faint bands were still detected possibly due to the blocking peptide not binding 
to all available epitopes (the epitopes to blocking peptide ratio was higher). 
This confirmed that the multiple bands of different molecular weight detected 
with the heregulin antibody were specific to this reaction. The bands greater 
than 85 kDa were not in keeping with the molecular weight of other NRG1 
alpha and beta isoforms detected with this anitbody. Similar findings have 
been reported in studies looking at the processing of NRG1 proteins (Montero 
et al. , 2000), and it is thought that these high molecular weight bands may 
represent the uncleaved NRG1 proprotein. 
6.2.3 Western blot analysis of heregulin expression in matched normal/ 
tumour samples 
Western blot analysis was carried out on a panel of 3 matched normal/tumour 
colorectal samples (Table 6.3). These tumours had not been characterised for 
8p12 deletions. 
. Tumour samples Early/Advanced 
... ·· .. ,. tumour ...... 
58T Early 
Table 6.3 7T Advanced 
ST Advanced 
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190 
86 
70 
47 
25 
22 
17 
5T 5N 7T 7N 58T 58N MW 
52 kDa --+ Cytokeratin 8 
Figure 6.3: Western blot of heregulln protein expression in 
matched normal/tumour samples: Multiple bands were noted in 
matched normal/tumour samples. In tumour samples the bands were 
not as intense as in the matched nonnal samples despite equal gel 
loading. 
Immunocytochemistry showed reduced intensity of staining in normal colorectal 
tissue compared with tumours. This is not what was found by western blotting. It is 
difficult to correlate the immunocytochemistry findings with western blotting. We next 
went on to investigate whether the immunohistochemistry findings in tumour samples 
with and without deletion were identified on Western blot analysis. 
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6.2.4: Expression of heregulin in a panel of adenomas, early and advanced 
tumour samples with and without deletion 
Samples used for this analysis are shown in Table 6.1a. A range of bands of varying 
molecular weight 190kDa to 39kDa were noted in normal mucosa and adenoma 
samples. Smaller molecular weight bands were seen in ear1y and advanced tumours 
as shown in Figure 6.4. 
20~0 
52KD 
7A 00 E 64 E 6L 16L 33L 38L 46L 
206KD---. ---
80KD 
39KD 
Samples without 
deletion. 
Samples with 
deletion. 
Figure 6.4: Western Blot of tumour samples with and without deletion. 
Multiple fragments of different molecular weight were noted in all samples. 
In advanced tumours with deletion the intensity of the high molecular weight 
bands were reduced and increased fragments of low molecular weight were 
noted. N= Normal mucosa, A= Adenomas, E = Early (T1 rr2 NOMO) tumour 
L = Advanced(T3fr4 NO/N1 MO/M1) tumours. 
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Similar findings were also noted in earfy tumours with and without c8p12 deletion. 
With progression towards advanced tumour stages, bands ranging from -86-25kDa 
were noted in the advanced tumour samples. Even though only a small number of 
tumour samples was analysed, bands of low molecular weight were more apparent in 
advanced tumours without deletion compared with advanced tumours with deletion 
(Figure 6.4). In advanced tumours with no deletion (samples 65- 67) the intensity of 
the -190kDa band was faint and the intensity of the other fragments (ranging from 
-86-17kDa) was increased. Similar findings had been previously noted in the 
matched normal/tumour colorectal samples (Figure 6.3). 
Although immunohistochemical data showed significant increased expression of 
heregulin protein in advanced tumours, this finding was not consistent with Western 
Blot analysis. Bands of varying molecular weight and intensity were noted throughout 
all samples. The high molecular weight bands were less apparent in advanced 
tumours (samples 65-67) without deletion compared with the advanced tumour group 
with deletion. 
6.3 Discussion 
Western blot analysis of heregulin protein using the C-terminal antibody revealed 
multiple bands of varying molecular weight in colorectal tumours. It was difficult to 
explain the findings of Western blot analysis in matched normal/tumour samples and 
in tumour samples with 1 without deletion. A review of current literature on NRG1 has 
shown similar findings on Western blot analysis (Montero et al. , 2000). 
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I mmunoprecipitation and Western blot studies have shown that deavage of 
transmembrane neuregulins, generates multiple cell bound truncated fragments 
detected with an anti-endodomain antibody (Figure 6.5). 
~ Mature~ Immature~ TNncated~ 
- PMA. ,., kD 
- 194 
-120 
I - 82 
- 51 
- 38 
-
Cells 
Montero et a/ 2000 
Figure 6.5: Processing of pro-NRG. The figure above shows deavage 
of pro -NRG. The processing of the neuregulin proteins has been shown 
to be stimulated by activation of PKC (protein kinase C) with PMA 
(phorbal myrisate acetate) whidlled to several truncated cell-bound 
fragments being generated. 
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Type I transmembrane NRG11igands such as heregulin are cleaved to release 
bioactive EGF domain. In advanced tumours, high and low molecular weight 
fragments were noted but in advanced tumours without deletion (samples 65~7), low 
molecular weight bands were predominant . We investigated whether mutations at 
the cleavage site (transmembrane domain) were responsible for the Western Blot 
findings in advanced tumours with and without deletion by sequencing of the 
transmembrane domain of matched normal/tumour samples with and without 
deletion. 
A SNP (single nucleotide polymorphism ) was identified in the transmembrane 
domain of sample 65 (no deletion at the c8p12 locus). Review of the transmembrane 
domain sequence (Ensembl, currently release 43- Feb 2007) did not identify any 
reported SNP in this region, therefore this represents a novel, previously unreported 
mutation. It is difficult to comment on the relevance of this mutation as it was 
detected in the patients normal and matched tumour sample. 
This SNP identified in the coding sequence of the transmembrane domain was a 
missense mutation leading to change in the amino acid sequence. Sequence 
analysis of transmembrane domain did not explain the range of high and low 
molecular weight fragment see on Western Blotting. Further studies will need to be 
undertaken on a large panel of tumours to establish if this missense mutation 
accounts for differences observed on Western blot analysis. 
These bands may also represent alternative spliced isoforms of NRG1 . Since 
limitations in the range of NRG1 antibodies available prevented further analysis of 
126 
NRG1 proteins, we went on to investigate the possibility that the Western blot 
reflects changes in relative expression levels of alternatively spliced isofoms using 
qualitative and semi-quantitative PCR. 
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RESULTS 
CHAPTER 7 
Analysis of NRG1 isoform expression in 
colorectal tumours. 
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7.1 Introduction 
One challenge with investigating NRG1 gene products in tumourigenesis is 
the possibility of changes in the splicing profile during the process of tumour 
formation. Since no single antibody can reliably detect all isoforms, it is 
possible that some of the changes seen in Western blotting may result from a 
change in splicing patterns between the isoforms detected by the antibody 
(alpha and beta isoforms) and those not detected (NRG1-gamma, GGF, 
NDF43, SMDF). We therefore established specific RT -PCR assays, to 
investigate alternative spliced products of NRG1 in colorectal tumours. 
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7.2 RESULTS 
7.2.1 Clinicopathological status of tumour samples used for NRG1 
isoform analysis: 
A cohort of ten advanced (T3fT 4, NO/N1 MO) colorectal tumour samples aAd 
were selected. Matched normal samples were included to investigate for any 
change in isoform expression between normal and tumour samples as shown 
in Table 7.1 below). 
Samples Histology 
18N T3NOMO 
18T T3NOMO 
24T T3N1MO 
24N T3N1MO 
28T T3NOMO 
28N T3NOMO 
33T T4N1MO 
33N T4N1MO 
35T T3NOMO 
35N T3NOMO 
38T T4NOMO 
38N T4NOMO 
46T T4N1MO 
46N T4N1MO 
12T T4N1MO 
12N T4N1MO 
29T T4NOMO 
29N T4NOMO 
4T T3NOMO 
Table 7.1: 4N T3NOMO 
Histopathological staging of tumour samples used for NRG1 isoform 
analyses 
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7 .2.2 Quality of synthesised eDNA 
8-actin RT -PCR was carried out to validate the quality of the eDNA 
synthesised. All of the PCR products were resolved on an agarose gel as 
shown in Figure 7.1 . 
------------~~- ---- -- ~ 223bp 
MW 18T 18N 24T 24N 28T 28H 33T 33H 35T 35H 38T 38N 46T 46N BxPC3 ~0 4T 4N 12T 12N 29T 29N 
Figure 7.1 : B-actin RT -PCR on a panel of matched normal/tumour 
samples. The quality of the eDNA synthesised from extracted RNA of matched 
colorectal tumour samples was assessed by RT -PCR. Primers to the house 
keeping gene 8-actin were used. Sui of the PCR product was run alongside O.Sug 
of 1 00 bp DNA ladder on a agarose gel. As shown above for all of the samples 
strong intensity bands were seen indicating that eDNA synthesis was of good 
quality. The pancreatic cell line eDNA (BxPC3) and H20 were used as positive and 
negative controls respectively. 
7.2.3: Design of primers to distinguish between different NRG11soforms 
Oligonucleotide primer sequences, which flank the alternative spliced region, 
were designed. The mRNA sequence of each isoform was obtained from the 
NCBI database. The exon and intron sequence of the NRG1 gene (shown in 
Figure 7.2a) was obtained from genomic database (NCB I and ensembl 
website). Primers were designed (using the Primer 3 output programme, 
http://frodo.wi.mit.edu/cgi-bin/primer3) across intron- exon boundaries of 
those exons that distinguished between the different isoforms. Each primer 
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I 
1 
I I 
571606 291665 2269 79562 596 4786 2775 2810 
Figure 7.2a: Exon I intron sequence of the NRG1 gene 
This figure illustrates the intron/exon sequence of the the NRG1 gene. The 
green boxes represent exons of NRG1 gene and the black bars represent the 
introns with the size of each intron represented in blue. Exon ?represents the 
common EGF functional domain of the NRG1 gene and is found in all 
alternatively spliced isoforms. 
GGF2 
Gamma 
Beta 1 
Alpha 
ndf43 
SMDF 
Beta3 
Figure 7.2b: Primer design for NRG1 isoforms. lsoform specific primers were 
designed to distinguish between NRG1 isoforms. The bars illustrate amplicon size and 
position. The light blue box (exon 7) represents the common EGF domain and the 
transmembrane domain is shown in dark blue. 
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7 .2.4: Optimization of isofonn specific primers 
Identification of positive controls for NRG1 isofonns 
In this study, the following isoforms of NRG1 were investigated; NRG1-
Gamma, NRG1-Beta1 , NRG1-Beta 3, NRG1-Giial Growth factor 2 (GGF2), 
NRG1-Sensory motor derived factor (SMDF), NRG1 -Neu- diffrentiation factor 
(ndf43) and NRG1-Aipha. A literature search was carried out and RT-PCR 
with oligonucleotide ALL primer pair (which detects most of the NRG1 
isoforms) was performed on a panel of in house cell line eDNA's to identify 
positive controls for the ALL amplicon as shown in Figure 7.3 
150bp 
0 0 0 0 0 
("') m Cl) co ...... ("') ~ 0) 0 N co N N co > 0 ...... ("') 0) u. 0 ~ II) ("') 0 a. «< ...... N N 0 N ..... 0 )( Q> lh :r: :r: ~ 0 ..... m :::J ..... m ~ :::E 0 ..... _.J J: E 0 :::E UJ 0 J: s :r: ~ J: Cl) 
Q> :::E 
.:JI! 
en 
Figure 7.3: RT-PCR on a panel of cell line eDNA using ALL primer 
oligonucleotides. RT -PCR was carried out using the ALL primer pair 
on a panel of cDNAs from cell lines. The cell lines BxPC3, HEK 293 
and MDAMB 231 were identified as positive controls for isoform-specific 
RT -PCR analysis. 
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Human brain eDNA was used as a positive control for SMDF, GGF2 that are 
predominately expressed in neuronal tissues. The Beta isoforms are 
expressed in breast and pancreatic tissues so pancreatic cell line BxPC3 and 
MDA- MB231 breast carcinoma cell line were used as positive controls. HEK-
293 (human embryonic kidney cell line) was used as a positive control for 
HRG1- Gamma. 
7.2.5 Analysis of NRG1 isoform expression by RT-PCR 
lsoform specific RT -PCR experiments were carried out on 1 0 matched 
normal/tumour colorectal samples as shown in Figure 7 .4. 
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Figure 7.4: lsoform specific RT -PCR on 10 matched normal/tumour colorectal 
samples. lsoform specific RT-PCR confirmed that Beta 1 and Beta 3 were expressed 
in colorectal samples. No qualitative change in isoform expression was noted in the 
samples. The NRG1-alpha isofom was detected in 9/10 matched normal/tumour 
samples. Differential expression of isoform gamma and ndf-43 was noted. In 2/10 
matched pairs, ndf-43 was only expressed in normal colonic mucosa. In 3/10 matched 
samples gamma isoform was expressed in normal and tumour samples and only 
expressed in tumour sample 
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The results of this exercise, summarised in Table 7.2 demonstrated that the 
tumours reviewed expressed essentially similar NRG1 isoform profiles as their 
matched normal mucosa. 
Expression of NRG1 isofroms in 10 matched 
nonnalllumour samples 
lsofonns Nonnal Tumour 
NRG1- Beta -1 10 10 
NRG1- Beta -3 10 10 
SMOF 0 0 
NRG1-Gamma 6 6 
NRG1-GGF2 0 0 
NRG1-Aipha 9 9 
NRG1-ndf-43 9 8 
Table 7_2 
In no case was GGFII or SMDF detected, while all tissues examined 
expressed beta-1 and beta-3. 9 of 1 0 of each series expressed alpha 
isoforms, while gamma and NDF43 were detectable in the majority of cases. 
These results indicate that no absolute shut-down or de novo expression of 
any NRG1 isoform occurs during tumour formation but this does not exclude 
the possibility of changes in the relative expression levels of each, since 
conventional RT -PCR cannot provide quantitative results. 
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Although the NRG1-Beta 1 isoform was expressed in all of the matched 
normal/tumour samples, 2 bands were noted in all of the samples (see Figure 
7.4 & 7.5). 
200bp __. Top Band 
100bp __. 
Figure 7.5: NRG1-beta 1 expression in matched normal/tumour 
colorectal samples. Following the isoform-specific RT-PCR 
analysis, PCR products of the beta 1 isoform of matched 
normal/tumours samples were resolved on a 3% agarose gel to 
allow further separation of the fragments of interest. 
In order to confirm Beta 1 isoform expression, sequencing of these fragments 
was performed. 
Sequencing of Beta 11soform: 
For this purpose the QIAquick gel extraction protocol was used (described in 
Chapter 2). The samples were analysed on a gel following elution (as shown 
in Figure 7.6). 
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The results of this exercise, summarised in Table 7.2 demonstrated that the 
tumours reviewed expressed essentially similar NRG1 isoform profiles as their 
matched normal mucosa. 
Expression of NRG1 isofroms in 10 matched 
norrnalltumour samples 
lsofonns Nonnal Tumour 
NRG1- Beta -1 10 10 
NRG1- Beta -3 10 10 
SMDF 0 0 
NRG1-Gamma 6 6 
NRG1-GGF2 0 0 
NRG1-Aipha 9 9 
NRG 1-ndf-43 9 8 
I Table 7_2 
In no case was GGFII or SMDF detected, while all tissues examined 
expressed beta-1 and beta-3. 9 of 10 of each series expressed alpha 
isoforms, while gamma and NDF43 were detectable in the majority of cases. 
These results indicate that no absolute shut-down or de novo expression of 
any NRG1 isoform occurs during tumour formation but this does not exclude 
the possibility of changes in the relative expression levels of each, since 
conventional RT -PCR cannot provide quantitative results. 
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Although the NRG1-Beta 1 isoform was expressed in all of the matched 
normal/tumour samples, 2 bands were noted in all of the samples (see Figure 
7.4 & 7.5). 
200bp __. Top Band 
100bp __. 
Figure 7.5: NRG1-beta 1 expression in matched normal/tumour 
colorectal samples. Following the isoform-specific RT-PCR 
analysis, PCR products of the beta 1 isoform of matched 
normal/tumours samples were resolved on a 3% agarose gel to 
allow further separation of the fragments of interest. 
In order to confirm Beta 1 isoform expression! sequencing of these fragments 
was performed. 
Sequencing of Beta 1 lsoform: 
For this purpose the QIAquick gel extraction protocol was used (described in 
Chapter 2). The samples were analysed on a gel following elution (as shown 
in Figure 7.6). 
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Top band 
l 
200bp 
100bp Bottom band 
Figure 7.6: Analysis of NRG1- Beta 1 isoform PCR products. Following DNA 
extraction the 5ul of each fragment of interest was run on a 2% agarose gel to 
check the yield. Samples were run against 0.5ug of 100bp DNA ladder.(100bp 
marker has a DNA mass of 48ng) 
Each fragment (top and bottom band) was taken through a PCR reaction 
using the Big Dye Cycle sequencing kit. The PCR products of the sequencing 
reaction were purified (Big Dye Version 3) and sequenced at the Functional 
Genomics Unit (University of Birmingham). 
Sequencing Data 
The sequencing data obtained for each fragment sequence was put through a 
Blast search (NCBI website) Sequence analysis demonstrated that the upper 
band contained exon 1 0 sequence and was therefore the expected 17 4bp 
NRG1-Beta 1 PCR amplicon. Sequence analysis of the lower band identified 
a clone similar to the NRG1-alpha isoform. 
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Over all no consistent qualitative change in isoform expression was detected. 
To extend these data we also performed a partial review, by semi-quantitative 
real-time RT-PCR, of the expression levels of beta-1 , beta-3 and NDF43 in a 
series of 5 early and 5 advanced cancers, compared with matched normal 
mucosa. Semi- quantitative real- time PCR was used to further evaluate the 
above findings. Real-time PCR was also used to examine whether secretory 
or transmembrane isoforms were predominately expressed in colorectal 
tumours. 
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7.3 Semi-quantitative Real-time RT-PCR analysis of NRG1 isoform 
expression in colorectal tumours 
Having confirmed expression of NRG1 isoforms Beta1 , Beta 3, Gamma and 
ndf43 in colorectal tumours, the expression levels of these isoforms were 
investigated by semi-quantitative real-time RT-PCR in a series of 5 early and 
5 advanced cancers, compared with matched normal mucosa (Table 7.3). 
Early tumours were also selected to investigate for any correlation between 
tumour stage and expression of NRG1 isoforms. 
Tumour Stage 
T3NOMO 
18 (advanced) 
T3NOMO 
35 (advanced) 
T3N1MO 
24 (advancedl 
T4NOMO 
38 (advanced) 
T4NOMx 
29 (advanced) 
T1NOMO 
60 {early) 
T2NOMO 
54 (earlyl 
T2NOMO 
73 (early) 
T2NOMO 
53 (early} 
T2NOMO 
58 (early) 
Table 7.3: Histopathological staging of tumour samples used for real-
time analysis 
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7.3.1: Design of primers to distinguish between different NRG1 lsoforms 
The Beta-1 and ndf-43 isoform specific primers were designed across exon/ 
intron boundaries (across exon 10, unique to Beta-1 and exon 15, unique to 
ndf-43). Primers to isoform Gamma were designed across the sequence of 
exon 7 unique to this isoform. This primer was not designed across exon I 
intron boundary as the amplicon would have been too large for real-time 
analysis. DNase treated RNA was used as a negative control for each 
matched normal/tumour sample. Similarly, the Beta-3 isoform primer was 
designed across exon 9. Although this sequence (exon 9) is present in NRG1 
isoforms SMDF and GGFII, real-time RT -PCR with Beta -3 oligonucleotide 
primers can only detect the Beta-3 amplicon, as both GGFII and SMDF were 
not expressed in colorectal tumours. Due to the nature of the sequence it 
proved too difficult to design a NRG1-alpha specific real time RT-PCR assay. 
7.3.2: Optimization of isoform specific primers 
The CT (cycle threshold) values obtained for each primer pair are shown in 
Table 7.5 a & b. The PCR products were run on a gel to check that the Ct 
values were not a result of primer-dimer formation (Figures 7.6 a,b ,c and d). 
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Optimization of Beta -1 and ndf-43 isoform specific primers. 
Pnmer Sample primer cone CT Awrage~ 
B eta 1 BXPC3 50/ 50 39.12 
B eta 1 BXPC3 50/ 50 39.25 39.25 
Beta 1 BXPC3 50/50 37.14 
Beta 1 BXPC3 300/300 23.61 I 
Beta 1 BXPC3 300/300 23.44 23.44 
Beta 1 BXPC3 300/300 23.19 
B eta 1 BXPC 3 900/900 22.76 
B et a 1 BXPC3 900/900 22.65 22.65 
Beta 1 BXPC3 900/900 22.39 
Beta 1 H20 300/300 40 
Beta 1 H20 300/300 38.28 38.28 
Beta 1 H20 300/300 40 
ndf BXPC3 50/ 50 40 
ndf BXPC 3 50/ 50 40 40 
ndf BXPC3 50/50 40 
ndf BXPC3 300/300 23.14 
ndf BXPC3 3 00/ 300 23.07 23.07 
I ndf BXPC3 300/300 22.62 
ndf BXPC3 900/900 22.59 
ndf BXPC3 900/900 22.47 22.47 
ndf BXPC3 900/ 900 22.34 
ndf H20 300/300 40 
ndf H20 300/300 40 40 
ndf H20 300/ 300 40 
Table 7 .4a: The Cr values obtained from different primer 
dilutions are shown in the tabl1e above. The figures in red 
represent the primer dilutions used for real-time PCR 
analysis. For Beta-1 isoform, although the Cr values for 
the 900/900 primer dilution were better, no significant 
difference in the intensity of PCR product was noted on the 
gel for 300/300 and 900/900 primer dilutions. Therefore a 
primer dilution of 300/300 was chosen. A primer dilution of 
900/900 for ndf-43 primer revealed product of increased 
intensity on the gel which corresponded with Cr values. 
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Primer 
dilutions+ 50/50 300/300 900/900 H20 
_, ~ .• ,,. 
.. ~· .. w:~ -f~. -- -
Fig: 7.7a 
Primer_. 
dilutions 
50/50 300/300 900/900 H20 
Fig: 7.7b 
The PCR products of Beta-1 primer (Fig 7.7a) 
and ndf43 primer (Fig 7.7b) optimisation were 
run on an Agarose gel stained in SYBR Green 
dye (1 in 200 dilution) 
Optimization of Gamma and Beta-3 isofonn specific primers. 
Primer Sample Primer Cr AwrageCr 
Gamma BxPC3 50/50 40 
Gamma BxPC3 50/50 40 40 
Gamma BxPC3 50/50 40 
Gamma BxPC3 300/300 32.12 
Gamma BxPC3 300/300 33.23 32.816667 
Gamma BxPC3 300/300 33.1 
Gamma BxPC3 900/900 28.11 
Gamma BxPC3 900/900 28.74 28.538667 
Gamma BxPC3 900/900 28.76 
Gamma H20 300/300 40 
Gamma H20 300/300 39.61 39.87 
Gamma H20 300/300 40 
Beta 3 Brain 50/50 30.24 
Beta 3 Brain 50/50 31 .1 30.276667 
Beta 3 Brain 50/ 50 29.49 
Beta 3 Brain 300/300 22.04 
Beta 3 Brain 300/300 23.07 22.74 
Beta 3 Brain 300/300 23.11 
Beta 3 Brain 900/900 22.72 
Beta 3 Brain 900/900 22.91 25. 166667 
Beta 3 Brain 900/900 29.87 
Beta 3 H20 300/300 40 
Beta 3 H20 300/300 40 40 
Beta 3 H20 300/300 40 
Table 7.4b: The Cr values obtained from different primer 
dilutions are shown in the table above. The figures in 
pink represent the primer dilutions used for subsequent 
real-time PCR analysis. For Gamma and Beta-3 primer 
pairs the Cr values correspond with the findings on the 
gel. 
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Primer 
dilutions+ 50/50 300/300 900/900 H20 
Fig: 7.7c 
Primer~ 50/50 300/300 900/900 H20 dilutions 
Fig: 7.7d 
Figure 7.7c&d: The PCR products of Gamma (Fig 
7.7 c) and of Beta -3 (Fig 7.7 d) primer optimisation 
were run on an Agarose gel stained inSYBR Green 
dye (1in 200 dilution) 
7.3.3 Analysis of NRG1 isoform expression by Real-time RT-PCR 
Cytokeratin-8 (KRT -8) an epithelial cell marker was use as an internal control. 
The expression of cytokeratin 8 was consistent between normal and tumour 
samples (Data not shown). The NRG1 isoform expression in each matched 
normal and tumour colon sample was standardised to KRT8 gene expression. 
The expression of each NRG1 isoform in tumours was normalised to the 
mean expression of each NRG1 isoform in matched normal mucosa. 
Expression of NRG1 isoforms is given by 2"-Mct, where -llllCr =11 Cr tumour 
-11Cr normal . 
Figure 7.8, shows how the isoform levels were altered in tumours compared 
with matched normal tissue. 4 of the 5 early tumours showed overall 
decreased expression of at least 2 of the 3 transcripts reviewed, in many 
cases by a factor of 5 to 10, although in one case (53T) transcript levels were 
significantly increased compared with normal tissue, by up to 35-fold in the 
case of beta-1. In advanced cancers, the results were more heterogeneous 
with reductions of 1 0- to 1 00-fold in some cases and inductions in the 1 0- to 
20- fold range in others, but no consistent pattern emerged between the cases 
investigated. 
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Real-time analysis of NRG1 isoform expression in colorectal 
tumours. 
Fold 
expression vs 
nonnals 
100.00 
10.00 
1.00 
0.10 
0.01 
Early tumours 
Table 7.5: Expression levels 
of NRG1 isoforms 
Tumour 
60 
54 
73 
58 
53 
18 
35 
24 
38 
29 
Advanced tumours 
24 
Beta 1 NDF 
0.22 0.11 
0.17 0.18 
0.36 0.50 
0.17 0.16 
35.02 3.32 
0.02 0.02 
16.34 0.1 9 
1.80 12.50 
0.67 0.10 
1.32 1.34 
29 
I !'IF 
D Beta3 
1 Beta 1 
Bata3 
0.49 
0.13 
1.19 
0 .96 
6.28 
0.12 
0.01 
8.09 
3.53 
0.74 
Figure7.8: The figure above shows real-time RT-PCR quantitation of NRG1 isoforms 
mRNA expression levels in 10 matched colorectal tumours. Samples 18, 35, 24, 38 & 
29 are advanced tumours and samples 60,54, 73, 53,& 58 are early tumours. To 
normalise for the quality and quantity of eDNa, the expression of each isoform was 
normalised to the cytokeratin 8 gene. The expression level of each isoform for each 
tumour sample was normalised to the mean value obtained for the matched normal 
mucosa. The expression level was calculated using 2 A-dder where ddC r = dC r of 
tumour sample- dC r of normal. The expression levels are shown on a logarithmic 
scale. No clear trend towards transmembrane or soluble isoforms being expressed 
during different stages of colorectal tumour progression was identified. 
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Real-time analysis of Gamma lsoform: The CT values obtained for this 
isoform were simHar for both the positive and negative control triplicate 
reactions. This finding was explained by primer-dimer formation seen when 
the PCR products were run on a gel. Although the SYBR Green mastermix 
used for real-time PCR was subsequently purchased form a different 
company (Quantace) the CT values were similar to previous results seen 
when using the original SYBR Green mastermix (Applied Biosystems). To 
prevent primer dimmer formation different concentrations of MgCI were used 
as shown in Figure 7.6 and Table 7.7. Despite altering the PCR reaction 
conditions, the CT values did not correspond with the gel findings. 
Mga 
cone 
Primer Sample C., values (mM) 
Gamma ~0 32.41 2 
Gamma ~0 31.49 2.5 
Gamma ~0 31 .36 3 
Gamma ~ 31 .68 3.5 
Gamma ~0 31 .15 4 
Gamma ~ 31 .24 4.5 
Gamma ~ 31 .36 5 
Gamma ~0 31 .2 5.5 
Gamma BxPC3 I 30.17 2 
Gamma BxPC3 29.89 2.5 
Gamma BxPC3 30 3 
Gamma BxPC3 31 .52 3.5 
Gamma BxPC3 31 .67 4 
Gamma BxPC3 31 .87 4.5 
Gamma BxPC3 30.01 5 
Gamma BxPC3 30.09 5.5 
Table 7.6: Real-time PCR with 
Gamma primers (900/900dilution) 
using different concentrations of 
MgCI 
- . 
- .. ·• . ..•. .. •. 
H~ BxPC3 
Figure 7.9: Gamma real-time PCR products 
were run on a gel stained with SYBR Green 
solution (1 in 200). The first 8 lanes following 
the MW marker show the PCR products 
obtained using H20 (negative control) with 
increasing concentrations of MgCI as shown in 
Table 7.7. In the remaining lanes the PCR 
product for positive control is shown. 
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This is one of the limitations of SYBR Green dye, as it binds any double 
stranded DNA and cannot distinguish between specific and non-specific 
products accumulated during the PCR reaction. As the CT values were not 
reliable this prevented further real-time analysis of the NRG1 gamma isoform. 
7.4 Discussion 
The expression of NRG1 isoforms was reduced in the early tumours, 
compared with advanced tumours. This change was consistent in 4/5 (80%) 
of early tumours. In the advanced tumour, group upregulation of atleast one 
isoform was noted in 3/5 (60%) tumours. Unlike the earfy tumour group, no 
consistent change in isoform expression was noted in advanced tumours, 
Deletion of one allele of NRG1 was found in 4/5 advanced (except tumour 29) 
and 2/5 early tumours. Tumour samples 53, 58 and 73 had not been 
previously investigated for deletion of NRG 1. In early tumour group with 
deletion (60T and 54T), decreased expression of all NRG1 isoforms was 
noted compared with matched normal controls. This was not the case in 
advanced tumour group with deletion where upregulation of atleast one 
isoform was noted in 3/4 (75%) tumours. 
Real-time RT-PCR isoform analysis confirms increased expression of NRG1 
isoforms in advanced tumours in the presence of deletion. Limitations in 
primer design prevented complete analysis of NRG1 isoform expression by 
real-time RT-PCR. Although transmembrane (Alpha, Beta-1and ndf-43) and 
secretory (Gamma, Beta-3) isoforms are expressed in colorectal tumours it 
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was not possible to establish which forms are predominately expressed due to 
study limitations. 
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Chapter 8 
Discussion 
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8.1 Discussion 
Loss of heterozygosity studies identified a distinct region of interstitial deletion at 
c8p12 locus in ear1y (T1) cancers (Chughtai et al1999). Interstitial deletions normally 
correspond to tumour suppressor genes, but the behaviour at c8p12 in colorectal 
tumours is more complex. Deletions at c8p12 were more frequent in early than 
advanced colorectal tumours (Chughtai et al 1999). Further studies (Adams, 2004) 
defined more closely this interstitial deletion, implicating a cluster of genes close to 
marker D8S259 in early colorectal cancer. One explanation for these findings at 
c8p12 is that both tumour suppressive and oncogenic effects reside at this locus. 
These activities could reside in two closely-linked genes or a single gene capable of 
showing both actions. We investigated NRG1, one of the genes in this region in 
colorectal tumours. 
In this study deletion (loss of one allele) of NRG1 was identified in early tumours 
with previously characterised 8 p12 deletions. Although the number of tumour 
samples studied were small, analysis of the ploidy status of these tumours revealed 
two groups; aneuploid and euploid tumours. Homozygous loss of NRG1 was 
detected in the euploid tumours compared to the aneuploid group. An increased 
range of DNA copy number alterations of both the 8 centromere and NRG1 gene 
was observed in the aneuploid group of tumours. The NRG1 copy number varied 
directly with the 8 centromere signal and was statistically significant. Chromosomal 
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gains and losses have been previously reported in aneuploid tumours (Reid et al., 
1999; Sugai et al. , 2003). 
Investigation of NRG1 protein (heregulin) identified significantly increased 
expression in more advanced cases compared with adenomas and earty tumours. 
In this study, small sample numbers prevented any meaningful analysis of whether 
NRG1 deletions had any effect on NRG1 protein expression. However a recent study 
by Prentice et al. (2005) did not identify any correlation between NRG1 deletions and 
protein expression in a multiple tissue array of breast tumours. MTA analysis did not 
identify any correlation between stage and heregulin expression in colorectal 
tumours examined. Although increased expression of heregulin has been reported 
with tumour stage in tissue microarray of invasive breast tumours (Prentice et al., 
2005), limited information regarding tumour grade in this study prevented further 
analysis. 
Overexpression of erb82 protein was identified in 9% (15/165) of colorectal 
tumours, which was in keeping with published reports (Ramanathan et al., 2004). In 
this study, no statistical difference was noted between tumour stage and erb82 
protein overexpression. Similar findings have been reported by Kim et al. (2004) in 
tissue microarray of colorectal tumours. However, MTA analysis of tumour samples 
identified a significant correlation between heregulin expression and erb82 protein 
overexpression in tumours (p=0.027). 
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Although the erb82 receptor proteins are reported at the basolateral membrane in 
normal airway epithelium (Vemeer et al. . 2003), both MTA and previous 
immunohistochemical analysis (Chapter 4), did not show this pattern of distribution in 
colon tumour epithelium. In normal mucosa, epithelial cell polarity and tight junctions 
maintain ligand-receptor segregation. Disruptions of tight junctions and epithelial cell 
polarity e.g. in response to tissue damage, allow ligand-receptor interaction and 
repair of damaged tissues. One possible explanation as to why a more diffuse 
pattern of membranous staining was seen in advanced tumours is that loss of normal 
tissue architecture will lead to disruption of epithelial cell polarity and tight junctions, 
thereby allowing receptor- ligand interation. 
Western Blot analysis did not show increased expression of heregulin in advanced 
tumours compared with adenomas and early tumours, instead multiple bands of 
varying molecular weight were noted. Although these bands could represent 
different NRG1 isoforms, studies investigating the processing of NRG1 proteins have 
reported similar findings and these bands of varying molecular weights are thought 
to represent cleavage products of the pro--protein (Monterro et al. , 2000). As already 
mentioned, cleavage of transmembrane proteins is necessary to allow protein 
signalling and release of bioadive EGF domain. Therefore it is possible that the 
increased number of low molecular weight protein bands seen in advanced tumours, 
are due to processing of NRG1 pro-protein. 
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RT-PCR analysis of NRG1 alternatively spliced isoforms did not identify any 
difference between which forms were predominantly expressed in matched normal 
and tumour samples. Semi-quantitative real-time RT -PCR, in early tumours showed 
overall decreased expression of at least 2 of the 3 transcripts reviewed, in many 
cases by a factor of 5 to 10, although in one case NRG1-beta 1 transcript levels 
were significantly increased in the tumour compared with normal tissue. In 
advanced cancers, the results were more heterogeneous with reductions of 1 0- to 
1 00-fold in some cases and inductions in the 1 0- to 20- fold range in others, but no 
consistent pattern emerged between the cases investigated. 
Having identified the region close to marker 088259 as the focus of this deletion in 
early tumours, NRG1 (which resides close to 088259) was an attractive target for 
further study, since the transmembrane isoforms contain both mitogenic EGF-related 
extracellular domains and pro-apoptotic intracellular domains (Montero et al., 2008; 
Le et al 2002). While the EGF action may dominate over apoptosis in unpolarised 
cells, in well-polarised epithelia heregulin, at least, is delivered to the apical 
membrane, segregating it from its basolateral receptor, and acts as a wound healing 
mitogen when tissue damage leads to Joss of polarity and allows interaction with 
ErbB receptors (Vermeer eta., 2003). Cleavage between the two domains by TACE 
(Montero et al., 2000) in a well-polarised tissue would however reveal the pro-
apoptotic function of the intracellular domain. Recent studies indicate that TACE 
activation is a consequence of beta-catenin-independent Wnt signalling, in tum 
promoted by the loss of soluble Wnt antagonists and the re-organisation of Wnt 
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response pathways early in tumourigenesis (Caldwell et al 2004, Caldwell et al 
2008). It is plausible that NRG1 loss is selected in well-polarised early tumours to 
evade apoptosis by this route. Thus, deletion allows the tumour to form, but the 
subsequent absence of the oncogene function prevents further development of the 
tumour. Tumours carrying c8p12 deletions can still progress however, although our 
evidence indicates that the deletion extends centromerically in more advanced 
cases, which may reflect a compensating loss of a further tumour suppressor. 
DUSP26 (MAP kinase phosphatase-B) is one of the genes in this region that 
encodes a dual specificity phosphatase that associates with p38 MAPK, inhibiting 
apoptosis and could have a potential role. 
Future studies 
Due to time restrictions, it was not possible to corroborate the findings of each 
analysis undertaken in a larger cohort of tumours. Below I have discussed some 
experiments which would strengthen the data. 
Although FISH analysis showed loss of NRG1 in early tumours, CGH array analysis 
on a large cohort of early and advanced tumours would establish whether loss of 
NRG1 is a more frequent event in early tumours compared with advanced tumours. 
Loss of one allele of NRG1 was detected in the advanced tumours with previously 
established c8p12 deletion but a clear difference in tumour behaviour was detected 
between the two groups of tumour samples. In early tumours, NRG1 deletion (loss of 
one allele) resulted in reduced expression of NRG1 protein but in advanced tumours 
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increased expression was noted. These findings warrants further investigation on a 
larger panel of early and advanced tumours with established 8p12 deletion. 
Fluorescent immunocytochemistry studies would allow apico-basal polarity of the 
ligand (heregulin) and erb82 receptors to be established in early and advanced 
colorectal tumours. As previously discussed loss of polarity and disruption of tight 
junctions allows receptor -ligand interaction to take place. Findings of Joss of polarity 
in advanced tumours compared to early tumours will provide evidence of oncogenic 
activity by heregulin in advanced tumours. 
Other Studies 
Establish a murine model to investigate NRG1 in colorectal tumourigenesis: 
The data reported in the thesis supports rather than refutes the original hypothesis 
that NRG1 plays a role in early and late colorectal tumourigenesis. In order to test 
this hypothesis further, however it will be necessary to perform functional studies in 
vivo. 
Pan-knock out studies of NRG1 in mice have shown the importance of neuregulin in 
development of the nervous system and heart during embryogenesis (Falls., 2003; 
Meyer et al., 1997) but this phenotype prevents more detailed study in adult tissue. 
Meaningful functional studies in animal models would therefore require conditional 
knock-out. Investigating NRG1 in a min-mice model will allow the effects of knock-
out I knock-in approaches. 
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Mice canying defects in APC, such as APC min , allow assessment of the impacts of 
tumour suppressor genes upon ear1y events in tumourigenesis . The current study 
was restricted to human tissues and the behaviour of NRG1 in APC-mutant mice is 
unknown, but this could be assessed using similar methodology. If it behaves in a 
similar manner in mice, conditional deletion of NRG1 in an APC .,. background 
would increase the number of adenomas formed if the hypothesis that it acts as an 
ear1y tumour suppressor is correct. Such a study could be extended to examine the 
contributions of individual isoforms by conditional deletion of their unique exons. The 
converse experiment, conditional over-expression of NRG1 , may also be informative. 
The APC +/min mice rarely progress to cancer. If NRG1- encoded factors contribute to 
progression, their overexpression may promote progression, which can be scored 
histologically. 
The combined data from these two approaches would provide robust evidence for a 
functional role in colorectal tumourigenesis which, in tum, could provide the basis for 
developing therapeutic approaches that target NRG1 . 
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